Propecia cheapest price

Kaufman and colleagues have considered the relationship between minimum wage and suicide mortality in the USA.1 Overall, they found that a dollar increase in the minimum wage was related propecia cheapest price to a meaningful 3.4% decrease in suicide mortality for those of lower educational attainment. Interestingly, this is the third paper in recent propecia cheapest price months to address the question of how minimum wage affects suicide. Across these papers, there is a remarkable overall consistency of findings, and important subissues are highlighted in each individual paper.The first of these papers, by Gertner and colleagues, found a 1.9% reduction in suicide associated with a dollar increase in the minimum wage across the total population.2 However, this research was unable to delve into the subgroup effects that would have allowed for a difference in differences approach, or placebo tests, due to their data source. First, Dow and colleagues,3 and then Kaufman and colleagues1 built on propecia cheapest price this initial finding with analyses of data that facilitated examination of subgroups. Both of these papers considered the group with a high school education or ….

Hair growth drug propecia

Propecia
Finast
Finpecia
Buy without prescription
Depends on the dose
Not always
Not always
How often can you take
Ask your Doctor
Best price for brand
Online Drugstore
Canadian Pharmacy
Indian Pharmacy

Here are hair growth drug propecia four of the most common causes of temporary hearing loss in children and what you should do if they Kamagra 100mg price in canada occur.1. Middle ear An ear exam can help reveal suddencauses of hearing loss in kids. According to the National Institute on Deafness and Other Communication Disorders (NIDCD), five of every six children will have at least one middle ear by their third birthday. In fact, ear s are hair growth drug propecia the most common reason parents take their child to the doctor. The good news is, although they can cause your child a lot of discomfort and hearing loss, ear s usually clear up on their own without any permanent damage to the hearing, although you should always check with your child's doctor.

The most common type of ear among children is known as acute otitis media (AOM). This occurs when parts of the middle ear become infected hair growth drug propecia and swollen, trapping fluid behind the eardrum. If your child isn’t old enough to tell you they have an earache, look for these symptoms. Tugging or pulling on the ear Crying and or general fussiness Problems sleeping Fever Fluid draining from the ear Balance issues Problems hearing or responding What to do about ear s Ear s are usually caused by bacteria from your child’s cold or sore throat that spread to the middle ear. Some methods hair growth drug propecia that can help your child feel more comfortable include.

Pain relievers, given according to direction and especially at bedtime to help your child get restful sleep Warm compress, such as a washcloth rinsed in warm water Lots of rest to help the body fight Your child may need antibiotics. Check in with your child's doctor to see if they recommend treatment. 2 hair growth drug propecia. Swimmer's ear If your child has been swimming recently—especially in non-chlorinated water like a lake or pond—it could be swimmer's ear, a type of of the ear canal. It can be quite painful and cause muffled hearing.

Children who are prone to getting water stuck hair growth drug propecia in their ears may be more likely to develop swimmer's ear. What do about swimmer's ear Keep the affected ear dry and clean Do not insert anything into the ears See a doctor to get antibiotic ear drops Follow your doctor's instructions for treating your child's pain 3. Impacted earwax It’s hard to believe, but earwax serves a purpose. Not only does hair growth drug propecia its waterproof properties help protect the eardrum and ear canal, it also traps dirt, dust and other particles from entering the ear and irritating the eardrum. Here’s another shocker.

The body produces just as much earwax as it needs and knows how to get rid of the excess. It’s OK to use a washcloth to gently clean hair growth drug propecia your child’s ear, but please don’t use cotton swabs or any other object to reach any accumulation you might see in the ear canal. These objects can actually push the earwax further into the ear canal and/or puncture the eardrum, causing more harm than good. What to do If your child complains he can’t hear well or sound is muffled, he may have an excess of earwax that is blocking the ear canal and preventing him from hearing well. In that case, hair growth drug propecia make an appointment with your family doctor.

If the earwax is causing pain or interfering with your child’s hearing, she will be able to remove the excess safely in just a few minutes. If it’s not earwax, it might be another type of obstruction. 4. Other obstructions By their very nature, kids are curious. As infants, they stick everything they can find into their mouths.

When they get a little older, they start discovering other body orifices to explore and may curiously try to see if something fits where it doesn’t belong–like in their ears. Common objects include pebbles, beans and small candies. Although it’s very normal for them to explore in this manner, it can lead to swelling, and temporary hearing loss. How can you tell if your child has put something into his ear?. You may not be able to immediately.

If the object is lodged far enough into the ear canal, you may not notice until your child complains of an earache or that things sound “funny.” You may possibly see some discharge from the ear, although not always. What to do If you suspect your child has something stuck in his ear. Remain calm. If your child is old enough to speak, ask them if they put something in their ear. Reassure them they are not in trouble and explain that it’s important to remove the object so they can hear.

Do not try to remove the object yourself, even if you can see it. You may push the object deeper into the ear canal and damage the eardrum. Call your doctor immediately. If she is not available to see your child, take them to the nearest walk-in clinic or emergency room. Let the medical professionals decide the best way to remove the object.

Afterward, they may prescribe antibiotics to prevent . It’s common for your child to be frightened at the thought of going to the doctor, especially when it’s a problem they caused. You can reassure them by explaining that removing the object won’t involve a shot or painful procedures. Ask your doctor or emergency room professional to explain any instruments they use before they begin the removal. To keep your child’s hearing in tip-top shape Wash little ears daily with a soft washcloth and warm water.

Do not insert anything into the ear canal, such as a cotton swab or hairpin, to remove earwax or other debris. Be mindful of hearing milestones and have your child’s hearing evaluated if they seem to have learning delays related to speech and language development. Model good communication skills. Be attentive and affirming, eliminate distractions such as cell phones and other electronic equipment, make eye contact and smile. Children are great mimics.

When you make hearing and communication a priority in your home, you instill good habits that will last them a lifetime. If you are concerned about your child's hearing ability, please find a hearing care professional in your area who specializes in pediatric hearing testing. Hearing testing can be done at any age and many children find it quite fun!.

He may be fussy and feverish or complaining that things “sound funny” or propecia cheapest price clogged Kamagra 100mg price in canada. Is it time to call the doctor?. Maybe. Here are four of propecia cheapest price the most common causes of temporary hearing loss in children and what you should do if they occur.1.

Middle ear An ear exam can help reveal suddencauses of hearing loss in kids. According to the National Institute on Deafness and Other Communication Disorders (NIDCD), five of every six children will have at least one middle ear by their third birthday. In fact, ear s are the most common reason parents take their child propecia cheapest price to the doctor. The good news is, although they can cause your child a lot of discomfort and hearing loss, ear s usually clear up on their own without any permanent damage to the hearing, although you should always check with your child's doctor.

The most common type of ear among children is known as acute otitis media (AOM). This occurs when propecia cheapest price parts of the middle ear become infected and swollen, trapping fluid behind the eardrum. If your child isn’t old enough to tell you they have an earache, look for these symptoms. Tugging or pulling on the ear Crying and or general fussiness Problems sleeping Fever Fluid draining from the ear Balance issues Problems hearing or responding What to do about ear s Ear s are usually caused by bacteria from your child’s cold or sore throat that spread to the middle ear.

Some methods that can help propecia cheapest price your child feel more comfortable include. Pain relievers, given according to direction and especially at bedtime to help your child get restful sleep Warm compress, such as a washcloth rinsed in warm water Lots of rest to help the body fight Your child may need antibiotics. Check in with your child's doctor to see if they recommend treatment. 2 propecia cheapest price.

Swimmer's ear If your child has been swimming recently—especially in non-chlorinated water like a lake or pond—it could be swimmer's ear, a type of of the ear canal. It can be quite painful and cause muffled hearing. Children who are prone to getting water stuck propecia cheapest price in their ears may be more likely to develop swimmer's ear. What do about swimmer's ear Keep the affected ear dry and clean Do not insert anything into the ears See a doctor to get antibiotic ear drops Follow your doctor's instructions for treating your child's pain 3.

Impacted earwax It’s hard to believe, but earwax serves a purpose. Not only propecia cheapest price does its waterproof properties help protect the eardrum and ear canal, it also traps dirt, dust and other particles from entering the ear and irritating the eardrum. Here’s another shocker. The body produces just as much earwax as it needs and knows how to get rid of the excess.

It’s OK to use a washcloth to gently clean your child’s ear, but please don’t use cotton swabs propecia cheapest price or any other object to reach any accumulation you might see in the ear canal. These objects can actually push the earwax further into the ear canal and/or puncture the eardrum, causing more harm than good. What to do If your child complains he can’t hear well or sound is muffled, he may have an excess of earwax that is blocking the ear canal and preventing him from hearing well. In that case, make an appointment with propecia cheapest price your family doctor.

If the earwax is causing pain or interfering with your child’s hearing, she will be able to remove the excess safely in just a few minutes. If it’s not earwax, it might be another type of obstruction. 4. Other obstructions By their very nature, kids are curious.

As infants, they stick everything they can find into their mouths. When they get a little older, they start discovering other body orifices to explore and may curiously try to see if something fits where it doesn’t belong–like in their ears. Common objects include pebbles, beans and small candies. Although it’s very normal for them to explore in this manner, it can lead to swelling, and temporary hearing loss.

How can you tell if your child has put something into his ear?. You may not be able to immediately. If the object is lodged far enough into the ear canal, you may not notice until your child complains of an earache or that things sound “funny.” You may possibly see some discharge from the ear, although not always. What to do If you suspect your child has something stuck in his ear.

Remain calm. If your child is old enough to speak, ask them if they put something in their ear. Reassure them they are not in trouble and explain that it’s important to remove the object so they can hear. Do not try to remove the object yourself, even if you can see it.

You may push the object deeper into the ear canal and damage the eardrum. Call your doctor immediately. If she is not available to see your child, take them to the nearest walk-in clinic or emergency room. Let the medical professionals decide the best way to remove the object.

Afterward, they may prescribe antibiotics to prevent . It’s common for your child to be frightened at the thought of going to the doctor, especially when it’s a problem they caused. You can reassure them by explaining that removing the object won’t involve a shot or painful procedures. Ask your doctor or emergency room professional to explain any instruments they use before they begin the removal.

To keep your child’s hearing in tip-top shape Wash little ears daily with a soft washcloth and warm water. Do not insert anything into the ear canal, such as a cotton swab or hairpin, to remove earwax or other debris. Be mindful of hearing milestones and have your child’s hearing evaluated if they seem to have learning delays related to speech and language development. Model good communication skills.

Be attentive and affirming, eliminate distractions such as cell phones and other electronic equipment, make eye contact and smile. Children are great mimics.

What is Propecia?

FINASTERIDE is used for the treatment of certain types of male hair loss (Alopecia). Finasteride is not for use in women.

Propecia canada reddit

Start Preamble Start Printed Page 15429 Centers for Disease Control and Prevention (CDC), Department of Health and Human propecia canada reddit Services (HHS). Notice with comment period. The Centers for Disease Control and Prevention (CDC), as part of its continuing propecia canada reddit effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a proposed and/or continuing information collection, as required by the Paperwork Reduction Act of 1995.

This notice invites comment on a proposed information collection project titled the National Ambulatory Medical Care Survey (NAMCS). The goal of this project is to assess the health of the population through patient use of physician and advanced practice provider offices and health centers (HCs), and to monitor the characteristics of physician and provider practices. CDC must receive written comments on or before May 17, propecia canada reddit 2022.

You may submit comments, identified by Docket No. CDC-2022-0038 by either of the following methods. • Federal eRulemaking Portal propecia canada reddit.

Regulations.gov. Follow the instructions for submitting comments. • Mail propecia canada reddit.

Jeffrey M. Zirger, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS H21-8, Atlanta, Georgia 30329. Instructions propecia canada reddit.

All submissions received must include the agency name and Docket Number. CDC will post, without change, all relevant comments to regulations.gov. Please note propecia canada reddit.

Submit all comments through the Federal eRulemaking portal (regulations.gov) or by U.S. Mail to propecia canada reddit the address listed above. Start Further Info To request more information on the proposed project or to obtain a copy of the information collection plan and instruments, contact Jeffrey M.

Zirger, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS H21-8, Atlanta, Georgia 30329. Phone. 404-639-7570.

Email. Omb@cdc.gov. End Further Info End Preamble Start Supplemental Information Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C.

3501-3520), federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. In addition, the PRA also requires federal agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each new proposed collection, each proposed extension of existing collection of information, and each reinstatement of previously approved information collection before submitting the collection to the OMB for approval. To comply with this requirement, we are publishing this notice of a proposed data collection as described below.

The OMB is particularly interested in comments that will help. 1. Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility.

2. Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used. 3.

Enhance the quality, utility, and clarity of the information to be collected. 4. Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submissions of responses.

And 5. Assess information collection costs. Proposed Project National Ambulatory Medical Care Survey (NAMCS) (OMB Control No.

0920-0234, Exp. 07/31/2024)—Revision—National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC). Background and Brief Description The National Ambulatory Medical Care Survey (NAMCS) was conducted intermittently from 1973 through 1985, and annually since 1989.

The survey is conducted under authority of Section 306 of the Public Health Service Act (42 U.S.C. 242k). NAMCS is part of the ambulatory care component of the National Health Care Surveys (NHCS), a family of provider-based surveys that capture health care utilization from a variety of settings, including hospital inpatient and long-term care facilities.

NCHS surveys of health care providers include NAMCS, the National Hospital Ambulatory Medical Care Survey (NHAMCS) (OMB Control No. 0920-0278, Exp. 09/30/2023), the National Hospital Care Survey (NHCS) (OMB Control No.

0920-0212, Exp. 03/31/2022), and National Post-acute and Long-term Care Study (NPALS) (OMB Control No. 0920-0943, Exp.

09/30/2023). An overarching purpose of NAMCS is to meet the needs and demands for statistical information about the provision of ambulatory medical care services in the United States. This fulfills one of NCHS' missions, to monitor the nation's health.

In addition, NAMCS provides ambulatory medical care data to study. (1) Performance of the U.S. Health care system, (2) care for the rapidly aging population, (3) changes in services such as health insurance coverage change, (4) introduction of new medical technologies, and (5) use of electronic health records (EHRs).

Ongoing societal changes have led to considerable diversification in the organization, financing, and technological delivery of ambulatory medical care. This diversification is evidenced by the proliferation of insurance and benefit alternatives for individuals, the development of new forms of physician group practices and practice arrangements (such as office-based practices owned by hospitals), the increasing role of advanced practice providers delivering clinical care, and growth in the number of alternative sites of care. Ambulatory services are rendered in a wide variety of settings, including physician/provider offices and hospital outpatient and emergency departments.

Since more than 65% of ambulatory medical care visits occur in physician offices, NAMCS provides data on the majority of ambulatory medical care services. In addition to health care provided in physician offices and outpatient and emergency departments, health centers (HCs) play an important role in the health care community by providing care to people who might not be able to afford it otherwise. HCs are local, non-profit, community-owned health care settings, which serve approximately 28 million individuals throughout the United States.

This Revision seeks approval to conduct changes to all three components of NAMCS. We plan to adjust the HC Component and Provider Interview sample sizes. In 2022 the goal is to sample 5,000 physicians, 5,000 advanced practice providers, and 110 HCs.

In 2023, we plan to sample up to 10,000 physicians, 20,000 advanced Start Printed Page 15430 practice providers, and 210 HCs, if funds allow. Lastly, if funds allow, in 2024 we will sample up to 20,000 physicians, 40,000 advanced practice providers, and 310 HCs. For 2022-2024, there will be an additional 3,000 physicians sampled yearly for the Provider Electronic Component.

Questions on the Health Center Facility Interview will be modified. After 2021, the Physician Induction Interview will shift to a redesigned Ambulatory Care Provider Interview. Visit data collection via abstraction will be placed on a hold and the reinterview study will be discontinued.

The provider incentive experiment will also no longer be taking place, as we will begin to conduct other methodological work to improve upon the survey. CDC requests OMB approval for an estimated 32,302 annual burden hours. There are no costs to respondents other than their time to participate.

Estimated Annualized Burden HoursType of respondentsForm nameNumber of respondentsNumber of responses per respondentAvg. Burden per response (in hrs.)Total burden (in hrs.)Physician or StaffOffice-Based Physician Induction Interview500130/60250 Reinterview Study42115/6011HC's StaffPrepare and transmit EHR for Visit Data (quarterly)17460/6068 Set-up fee questionnaire17115/604Physician or StaffACPI11,667130/605,834Advanced Practice Provider or StaffACPI21,667130/6010,834Ambulatory Care Provider's or Group's or Conglomerate's StaffPFI Prepare and transmit Electronic Visit Data (quarterly)3,000 3,0001 445/60 60/602,250 12,000HC's StaffHC Facility Interview210145/60158 Prepare and transmit EHR for Visit Data (quarterly)210460/60840 Set-up fee questionnaire210115/6053Total32,302 Start Signature Jeffrey M. Zirger, Lead, Information Collection Review Office, Office of Scientific Integrity, Office of Science, Centers for Disease Control and Prevention.

End Signature End Supplemental InformationStart Preamble Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS). Notice. HRSA is updating income levels used to identify a “low-income family” for the purpose of determining eligibility for programs that provide health professions and nursing training to individuals from disadvantaged backgrounds.

These various programs are authorized in Titles III, VII, and VIII of the Public Health Service Act. HHS periodically publishes in the Federal Register low-income levels to be used by institutions receiving grants or cooperative agreement awards to determine eligibility for programs providing training for (1) disadvantaged individuals, (2) individuals from disadvantaged backgrounds, or (3) individuals from low-income families. End Preamble Start Supplemental Information Many health professions and nursing grant and cooperative agreement awardees use the low-income levels to determine whether potential program participants are from economically disadvantaged backgrounds and would be eligible to participate in the program, as well as to determine the amount of funding individuals receive.

Awards are generally made to accredited schools of medicine, osteopathic medicine, public health, dentistry, veterinary medicine, optometry, pharmacy, allied health, podiatric medicine, nursing, and chiropractic. Public or private nonprofit schools which offer graduate programs in behavioral health and mental health practice. And other public or private nonprofit health or educational entities to assist individuals from disadvantaged backgrounds and disadvantaged students to enter and graduate from health professions and nursing schools.

Some programs provide for the repayment of health professions or nursing education loans for students from disadvantaged backgrounds and disadvantaged students. A “low-income family/household” for programs included in Titles III, VII, and VIII of the Public Health Service Act is defined as having an annual income that does not exceed 200 percent of HHS's poverty guidelines. A family is a group of two or more individuals related by birth, marriage, or adoption who live together.

Most HRSA programs use the income of a student's parent(s) to compute low income status. However, a “household” may potentially be only one person. Other HRSA programs, depending upon the legislative intent of the program, the programmatic purpose related to income level, as well as the age and circumstances of the participant, will apply these low income standards to the individual student to determine eligibility, as long as the individual is not listed as a dependent on the tax form of their parent(s).

Each program includes the rationale and methodology for determining low income levels in program funding opportunities or applications. Low-income levels are adjusted annually based on HHS's poverty guidelines. HHS's poverty guidelines are based on poverty thresholds published by the U.S.

Census Bureau, adjusted annually for changes in the Consumer Price Index. The income Start Printed Page 14019 figures below have been updated to reflect HHS's 2022 poverty guidelines as published in the Federal Register at 87 FR 3315. See https://www.federalregister.gov/​documents/​2022/​01/​21/​2022-01166/​annual-update-of-the-hhs-poverty-guidelines.

Low Income Levels Based on the 2022 Poverty Guidelines for the 48 Contiguous States and the District of ColumbiaPersons in family/household *Income level **1$27,180236,620346,060455,500564,940674,380783,820893,260For families with more than 8 persons, add $9,440 for each additional person.* Includes only dependents listed on federal income tax forms.** Adjusted gross income for calendar year 2021. Low Income Levels Based on the 2022 Poverty Guidelines for AlaskaPersons in family/household *Income level **1$33,980245,780357,580469,380581,180692,9807104,7808116,580For families with more than 8 persons, add $11,800 for each additional person.* Includes only dependents listed on federal income tax forms.** Adjusted gross income for calendar year 2021. Low Income Levels Based on the 2022 Poverty Guidelines for HawaiiPersons in family/household *Income level **1$31,260242,120352,980463,840574,700685,560796,4208107,280For families with more than 8 persons, add $10,860 for each additional person.* Includes only dependents listed on federal income tax forms.** Adjusted gross income for calendar year 2021.

Separate poverty guidelines figures for Alaska and Hawaii reflect Office of Economic Opportunity administrative practice beginning in the 1966-1970 period since the U.S. Census Bureau poverty thresholds do not have separate figures for Alaska and Hawaii. The poverty guidelines are not defined for Puerto Rico or other jurisdictions.

Puerto Rico and other jurisdictions shall use income guidelines for the 48 Contiguous States and the District of Columbia. Start Signature Carole Johnson, Administrator. End Signature End Supplemental Information.

Start Preamble Start Printed Page 15429 Centers for Disease Control and Prevention buy propecia merck (CDC), Department of propecia cheapest price Health and Human Services (HHS). Notice with comment period. The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public propecia cheapest price burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a proposed and/or continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled the National Ambulatory Medical Care Survey (NAMCS). The goal of this project is to assess the health of the population through patient use of physician and advanced practice provider offices and health centers (HCs), and to monitor the characteristics of physician and provider practices.

CDC must receive written comments on or before propecia cheapest price May 17, 2022. You may submit comments, identified by Docket No. CDC-2022-0038 by either of the following methods. • Federal eRulemaking propecia cheapest price Portal. Regulations.gov.

Follow the instructions for submitting comments. • propecia cheapest price Mail. Jeffrey M. Zirger, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS H21-8, Atlanta, Georgia 30329. Instructions propecia cheapest price.

All submissions received must include the agency name and Docket Number. CDC will post, without change, all relevant comments to regulations.gov. Please note propecia cheapest price. Submit all comments through the Federal eRulemaking portal (regulations.gov) or by U.S. Mail to the propecia cheapest price address listed above.

Start Further Info To request more information on the proposed project or to obtain a copy of the information collection plan and instruments, contact Jeffrey M. Zirger, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS H21-8, Atlanta, Georgia 30329. Phone. 404-639-7570. Email.

Omb@cdc.gov. End Further Info End Preamble Start Supplemental Information Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3520), federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. In addition, the PRA also requires federal agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each new proposed collection, each proposed extension of existing collection of information, and each reinstatement of previously approved information collection before submitting the collection to the OMB for approval. To comply with this requirement, we are publishing this notice of a proposed data collection as described below.

The OMB is particularly interested in comments that will help. 1. Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility. 2. Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used.

3. Enhance the quality, utility, and clarity of the information to be collected. 4. Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submissions of responses. And 5.

Assess information collection costs. Proposed Project National Ambulatory Medical Care Survey (NAMCS) (OMB Control No. 0920-0234, Exp. 07/31/2024)—Revision—National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC). Background and Brief Description The National Ambulatory Medical Care Survey (NAMCS) was conducted intermittently from 1973 through 1985, and annually since 1989.

The survey is conducted under authority of Section 306 of the Public Health Service Act (42 U.S.C. 242k). NAMCS is part of the ambulatory care component of the National Health Care Surveys (NHCS), a family of provider-based surveys that capture health care utilization from a variety of settings, including hospital inpatient and long-term care facilities. NCHS surveys of health care providers include NAMCS, the National Hospital Ambulatory Medical Care Survey (NHAMCS) (OMB Control No. 0920-0278, Exp.

09/30/2023), the National Hospital Care Survey (NHCS) (OMB Control No. 0920-0212, Exp. 03/31/2022), and National Post-acute and Long-term Care Study (NPALS) (OMB Control No. 0920-0943, Exp. 09/30/2023).

An overarching buy propecia online usa purpose of NAMCS is to meet the needs and demands for statistical information about the provision of ambulatory medical care services in the United States. This fulfills one of NCHS' missions, to monitor the nation's health. In addition, NAMCS provides ambulatory medical care data to study. (1) Performance of the U.S. Health care system, (2) care for the rapidly aging population, (3) changes in services such as health insurance coverage change, (4) introduction of new medical technologies, and (5) use of electronic health records (EHRs).

Ongoing societal changes have led to considerable diversification in the organization, financing, and technological delivery of ambulatory medical care. This diversification is evidenced by the proliferation of insurance and benefit alternatives for individuals, the development of new forms of physician group practices and practice arrangements (such as office-based practices owned by hospitals), the increasing role of advanced practice providers delivering clinical care, and growth in the number of alternative sites of care. Ambulatory services are rendered in a wide variety of settings, including physician/provider offices and hospital outpatient and emergency departments. Since more than 65% of ambulatory medical care visits occur in physician offices, NAMCS provides data on the majority of ambulatory medical care services. In addition to health care provided in physician offices and outpatient and emergency departments, health centers (HCs) play an important role in the health care community by providing care to people who might not be able to afford it otherwise.

HCs are local, non-profit, community-owned health care settings, which serve approximately 28 million individuals throughout the United States. This Revision seeks approval to conduct changes to all three components of NAMCS. We plan to adjust the HC Component and Provider Interview sample sizes. In 2022 the goal is to sample 5,000 physicians, 5,000 advanced practice providers, and 110 HCs. In 2023, we plan to sample up to 10,000 physicians, 20,000 advanced Start Printed Page 15430 practice providers, and 210 HCs, if funds allow.

Lastly, if funds allow, in 2024 we will sample up to 20,000 physicians, 40,000 advanced practice providers, and 310 HCs. For 2022-2024, there will be an additional 3,000 physicians sampled yearly for the Provider Electronic Component. Questions on the Health Center Facility Interview will be modified. After 2021, the Physician Induction Interview will shift to a redesigned Ambulatory Care Provider Interview. Visit data collection via abstraction will be placed on a hold and the reinterview study will be discontinued.

The provider incentive experiment will also no longer be taking place, as we will begin to conduct other methodological work to improve upon the survey. CDC requests OMB approval for an estimated 32,302 annual burden hours. There are no costs to respondents other than their time to participate. Estimated Annualized Burden HoursType of respondentsForm nameNumber of respondentsNumber of responses per respondentAvg. Burden per response (in hrs.)Total burden (in hrs.)Physician or StaffOffice-Based Physician Induction Interview500130/60250 Reinterview Study42115/6011HC's StaffPrepare and transmit EHR for Visit Data (quarterly)17460/6068 Set-up fee questionnaire17115/604Physician or StaffACPI11,667130/605,834Advanced Practice Provider or StaffACPI21,667130/6010,834Ambulatory Care Provider's or Group's or Conglomerate's StaffPFI Prepare and transmit Electronic Visit Data (quarterly)3,000 3,0001 445/60 60/602,250 12,000HC's StaffHC Facility Interview210145/60158 Prepare and transmit EHR for Visit Data (quarterly)210460/60840 Set-up fee questionnaire210115/6053Total32,302 Start Signature Jeffrey M.

Zirger, Lead, Information Collection Review Office, Office of Scientific Integrity, Office of Science, Centers for Disease Control and Prevention. End Signature End Supplemental InformationStart Preamble Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS). Notice. HRSA is updating income levels used to identify a “low-income family” for the purpose of determining eligibility for programs that provide health professions and nursing training to individuals from disadvantaged backgrounds. These various programs are authorized in Titles III, VII, and VIII of the Public Health Service Act.

HHS periodically publishes in the Federal Register low-income levels to be used by institutions receiving grants or cooperative agreement awards to determine eligibility for programs providing training for (1) disadvantaged individuals, (2) individuals from disadvantaged backgrounds, or (3) individuals from low-income families. End Preamble Start Supplemental Information Many health professions and nursing grant and cooperative agreement awardees use the low-income levels to determine whether potential program participants are from economically disadvantaged backgrounds and would be eligible to participate in the program, as well as to determine the amount of funding individuals receive. Awards are generally made to accredited schools of medicine, osteopathic medicine, public health, dentistry, veterinary medicine, optometry, pharmacy, allied health, podiatric medicine, nursing, and chiropractic. Public or private nonprofit schools which offer graduate programs in behavioral health and mental health practice. And other public or private nonprofit health or educational entities to assist individuals from disadvantaged backgrounds and disadvantaged students to enter and graduate from health professions and nursing schools.

Some programs provide for the repayment of health professions or nursing education loans for students from disadvantaged backgrounds and disadvantaged students. A “low-income family/household” for programs included in Titles III, VII, and VIII of the Public Health Service Act is defined as having an annual income that does not exceed 200 percent of HHS's poverty guidelines. A family is a group of two or more individuals related by birth, marriage, or adoption who live together. Most HRSA programs use the income of a student's parent(s) to compute low income status. However, a “household” may potentially be only one person.

Other HRSA programs, depending upon the legislative intent of the program, the programmatic purpose related to income level, as well as the age and circumstances of the participant, will apply these low income standards to the individual student to determine eligibility, as long as the individual is not listed as a dependent on the tax form of their parent(s). Each program includes the rationale and methodology for determining low income levels in program funding opportunities or applications. Low-income levels are adjusted annually based on HHS's poverty guidelines. HHS's poverty guidelines are based on poverty thresholds published by the U.S. Census Bureau, adjusted annually for changes in the Consumer Price Index.

The income Start Printed Page 14019 figures below have been updated to reflect HHS's 2022 poverty guidelines as published in the Federal Register at 87 FR 3315. See https://www.federalregister.gov/​documents/​2022/​01/​21/​2022-01166/​annual-update-of-the-hhs-poverty-guidelines. Low Income Levels Based on the 2022 Poverty Guidelines for the 48 Contiguous States and the District of ColumbiaPersons in family/household *Income level **1$27,180236,620346,060455,500564,940674,380783,820893,260For families with more than 8 persons, add $9,440 for each additional person.* Includes only dependents listed on federal income tax forms.** Adjusted gross income for calendar year 2021. Low Income Levels Based on the 2022 Poverty Guidelines for AlaskaPersons in family/household *Income level **1$33,980245,780357,580469,380581,180692,9807104,7808116,580For families with more than 8 persons, add $11,800 for each additional person.* Includes only dependents listed on federal income tax forms.** Adjusted gross income for calendar year 2021. Low Income Levels Based on the 2022 Poverty Guidelines for HawaiiPersons in family/household *Income level **1$31,260242,120352,980463,840574,700685,560796,4208107,280For families with more than 8 persons, add $10,860 for each additional person.* Includes only dependents listed on federal income tax forms.** Adjusted gross income for calendar year 2021.

Separate poverty guidelines figures for Alaska and Hawaii reflect Office of Economic Opportunity administrative practice beginning in the 1966-1970 period since the U.S. Census Bureau poverty thresholds do not have separate figures for Alaska and Hawaii. The poverty guidelines are not defined for Puerto Rico or other jurisdictions. Puerto Rico and other jurisdictions shall use income guidelines for the 48 Contiguous States and the District of Columbia. Start Signature Carole Johnson, Administrator.

Do propecia pills expire

Finding nurses willing to work at rural hospitals — a problem even before the propecia best place to buy propecia uk — has been do propecia pills expire partially solved by the use of temporary “traveling” nurses, experts said. But that solution comes with a cost. Hiring traveling nurses through a staffing agency do propecia pills expire can cost many times what hospitals pay local nurses. And some people worry that the traveling-nurse system may be creating another problem by luring staff nurses away to more lucrative temporary positions. But an industry expert said this claim is overblown do propecia pills expire.

According to ZipRecruiter, the pay for nurses in small towns ranges from $36,000 to $94,000. Some jobs offer signing bonuses, as do propecia pills expire well. In comparison, traveling nurses make anywhere from $5,000 a week to up to $9,500 a week, although nursing specialty can have a big impact on pay. Sites like Aya Healthcare list traveling-nurse jobs that last from a few weeks to a few months, with full benefits, housing, healthcare, and sick days. During the propecia, traveling nurses helped out in areas seeing the most patients do propecia pills expire – urban areas like New York and California.

During the surge of the Delta variant, traveling nurses helped out in more rural areas. Brock Slabach, chief do propecia pills expire operations officer with the National Rural Health Association, said the propecia has forced hospitals to rely more and more on traveling nurses. €œHospitals are having difficult times in recruiting/retaining workforce, and agency nurses, or traveling nurses, have historically filled temporary gaps in staffing.,” he said. “The propecia has caused excessive turnover in rural hospital staffing with a very do propecia pills expire limited supply of agency nurses, thus creating high prices to hire these nurses – as much as or over $200 per hour. This is unsustainable.

It also causes morale issues when agency nurses share what they’re making with staff nurses and it creates real morale issues.” For some nurses, he said, the lure of more money leads them to become traveling nurses. Another factor driving the increase in demand for traveling do propecia pills expire nurses at rural hospitals is treatment mandates, Slabach said. Like this story?. Sign do propecia pills expire up for our newsletter. “I’m hearing from hospital CEOs that the treatment mandate for health care workers being promulgated by the Biden administration will cause further attrition of staffing in rural hospitals,” he said.

€œThese CEOs support allowing weekly testing for hair loss treatment as an alternative to a treatment mandate.” But Dr do propecia pills expire. Nicole Rouhana with the Rural Nurse Organization, a nurse/midwife with a 40-year career in health care and program director at the State University of New York in Binghamton, said media reports of rural nurses becoming traveling nurses seem overblown. €œI think it’s gotten a lot of press, but I don’t think it’s as prevalent as everybody thinks it is,” she said. €œI mean, there are people do propecia pills expire who might have small children or they might want to go somewhere for two weeks and make a lot of cash and then come home to take care of their kids. We are seeing it, but it’s not lasting long.” Rouhana said she felt the use of traveling nurses would begin to wane a bit when the country gets hair loss treatment under control, over the next two or three years.

But by then, she said, the issue facing healthcare will be the increasing numbers of baby boomers aging and putting further strain on the healthcare system do propecia pills expire. Rural areas, whose residents tend to be older, poorer, and sicker, will need more nurses to care for them as they age. Already, healthcare organizations like RNO are working to recruit do propecia pills expire people into the nursing profession. The key to getting nurses to stay long-term in rural areas, she said, was recruiting people who already live there. €œIf we develop our Healthcare Workforce from within the communities, where they come from, we’re do propecia pills expire going to have a long-term provider,” she said.

€œThey raise their kids there. They were born and raised there. They might have land do propecia pills expire there. So their likelihood of them staying there long-term is much higher than if, for instance, we recruited somebody from an urban setting to come to the rural area. Research shows that they (urban recruits) usually stay in a rural setting for only two to three http://www.ec-duppigheim.ac-strasbourg.fr/rentree-des-classes/ years.” Other do propecia pills expire programs through the U.S.

Office of Health Resources and Services Administration provide scholarships for two-year nursing programs in exchange for a two-year commitment to work in a rural area, she said. Federal workforce grants are also available to do propecia pills expire provide students with tuition, laptops, clinical equipment and specialized training to care for rural populations, she said. €œWe can bypass all those recruitment and retention efforts that healthcare organizations are burdened with by, instead, doing focused recruitment from within our rural communities and saying to these nurses ‘Hey, you want to become a nurse practitioner?. I’ll pay you, you can do your training right in your community and then when you graduate, the people who trained you are probably going to want to hire you because you live in the community, you’re known and respected in the community and we trained you.’” You Might Also LikeCredit. Pixabay/CC0 Public do propecia pills expire Domain In the heart of a city, the distances in rural communities may be difficult to envision.

The space between neighbors can sometimes be measured in miles rather than blocks. A drive to the nearest hospital may take dozens of minutes do propecia pills expire rather than a handful. The trickle-down effect of such distances can impact many aspects of health care, but especially maternal care and delivery, says Mark Deutchman, MD, a professor of family medicine and associate dean for rural health at the University of Colorado School of Medicine.As principal investigator of a study recently published in the journal Birth analyzing the impact of family physicians in rural maternity care, Deutchman and his co-investigators found that of the 185 rural hospitals surveyed in 10 states, family physicians delivered babies in 67% of the hospitals and were the only physicians who delivered babies in 27% of them.Further, the study found that if family physicians stopped delivering babies in these rural hospitals, patients would have to drive an average of 86 miles round-trip to access maternal care."The purpose of this study was, number one, to understand the extent of family physicians providing maternity care in rural areas," Deutchman explains. "Number two, and even more important, was to understand what would happen to women if family practitioners did not do propecia pills expire practice maternity care, and that's the real take-home message. Family physicians are really, really important."Study highlights importance of family physicians providing maternity careOn this topic, Deutchman speaks from experience.

For more do propecia pills expire than 12 years he practiced family medicine in White Salmon, Washington, a town of 2,000 residents on the Columbia River. The local hospital is federally designated critical access, which means it has fewer than 20 beds, among other standards."One of the major things I was involved in was maternity care," he says. "I had a lot of OB patients and did a lot of deliveries. I was also one of the major providers of surgical OB, of C-sections when they were needed."I'm an advocate for and student of the quality of outcomes do propecia pills expire in areas where family physicians are a woman's provider of obstetric and gynecologic care. I think that women deserve to have excellent care no matter where they are and no matter who provides it." After leaving rural practice, Deutchman became a faculty member at the University of Tennessee-Memphis, where he helped train family medicine residents for rural practice.

He continued that focus after joining the University of Colorado School do propecia pills expire of Medicine in 1995. In 2005, he founded the school's rural track, which this year became a full-fledged program.His recently published research evolved from previous, similar studies he conducted in Colorado and Montana with medical students."It wasn't a study of quality—we weren't looking at individual cases and weren't looking at outcomes—but we wanted to better understand how much and the sort of maternal care family physicians are providing at rural hospitals," he explains.After refining the survey tool used in the previous studies, Deutchman reached out to colleagues across the country. Those who responded represented 10 states and collected data about rural and frontier hospitals in do propecia pills expire their states. They gathered data about the hospitals' obstetrics capacity, who delivers babies at the hospitals and what their specialty is, and other data."Ultimately, we were looking at how important is it for family physicians to provide maternity care and what would access be if they didn't?. " Deutchman says.Rural program provides specialized training needed for medical students and residentsThe study's results, Deutchman says, highlight the importance of comprehensive, specialized training for medical students and residents who are interested in practicing in rural communities."Basically, the rural program is a way to attract, admit and support medical students and physician assistant students who want to live and work in rural areas when they finish their training," he explains.

"We need to have a program so that people who are interested in rural practice will have their aspirations supported and also have a way to test their assumptions about rural practice and see if it's really right for them."The last thing we want is for students to have romanticized ideas, and then they show up in a small town and it wasn't what they do propecia pills expire had in mind. We also don't want to have that revolving door where physicians go to a small community for only two or three years, which fosters distrust and a lack of attachment between doctors and the community."Through the rural program, students not only receive on-campus experience in the classroom and clinical training, but they get significant rural clinic experience with partners throughout Colorado. That aspect of the training is vital, Deutchman says, do propecia pills expire because students learn in-person about rural health care systems and economics, community engagement, health care ethics, and how to practice in a community where physicians might regularly see patients at the grocery store.Since 2005, Deutchman says, 191 students in the CU School of Medicine have graduated in the rural track, 40% of whom concentrated on family medicine."A common question is, 'How do you get people interested in rural practice and providing care like delivering babies?. '" Deutchman says. "Partly, we start out with people who are initially interested, then we help nurture that interest with real facts and real do propecia pills expire practical experience."Basically, the whole state of Colorado is short of primary care, especially in rural areas, which cannot support one of every kind of sub-specialist.

Rural communities need versatile, broadly-trained and skilled physicians who can share clinical responsibilities with each other to avoid burnout. Family physicians can provide acute care, chronic care, end of life care, deliver babies, put on casts, repair lacerations—in the most accessible, cost-effective fashion. It's vital do propecia pills expire we train and support these physicians who go out and support these rural communities." Explore further Finding a doctor is tough and getting tougher in rural America More information. Mark Deutchman et al, The impact of family physicians in rural maternity care, Birth (2021). DOI.

10.1111/birt.12591 Provided by CU Anschutz Medical Campus Citation. Study finds family physicians deliver babies in majority of rural hospitals (2021, October 19) retrieved 22 October 2021 from https://medicalxpress.com/news/2021-10-family-physicians-babies-majority-rural.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only..

Finding nurses willing to work http://racheljenae.com/photography/animals/the-pups/ at rural hospitals — propecia cheapest price a problem even before the propecia — has been partially solved by the use of temporary “traveling” nurses, experts said. But that solution comes with a cost. Hiring traveling nurses through a staffing agency propecia cheapest price can cost many times what hospitals pay local nurses. And some people worry that the traveling-nurse system may be creating another problem by luring staff nurses away to more lucrative temporary positions.

But an industry expert said propecia cheapest price this claim is overblown. According to ZipRecruiter, the pay for nurses in small towns ranges from $36,000 to $94,000. Some jobs offer signing propecia cheapest price bonuses, as well. In comparison, traveling nurses make anywhere from $5,000 a week to up to $9,500 a week, although nursing specialty can have a big impact on pay.

Sites like Aya Healthcare list traveling-nurse jobs that last from a few weeks to a few months, with full benefits, housing, healthcare, and sick days. During the propecia, traveling nurses helped out in areas seeing the most patients propecia cheapest price – urban areas like New York and California. During the surge of the Delta variant, traveling nurses helped out in more rural areas. Brock Slabach, chief operations officer with the National Rural Health Association, said the propecia has propecia cheapest price forced hospitals to rely more and more on traveling nurses.

€œHospitals are having difficult times in recruiting/retaining workforce, and agency nurses, or traveling nurses, have historically filled temporary gaps in staffing.,” he said. “The propecia has caused excessive turnover in rural hospital staffing with a very limited supply of agency nurses, thus creating high prices to propecia cheapest price hire these nurses – as much as or over $200 per hour. This is unsustainable. It also causes morale issues when agency nurses share what they’re making with staff nurses and it creates real morale issues.” For some nurses, he said, the lure of more money leads them to become traveling nurses.

Another factor driving the increase propecia cheapest price in demand for traveling nurses at rural hospitals is treatment mandates, Slabach said. Like this story?. Sign up for propecia cheapest price our newsletter. “I’m hearing from hospital CEOs that the treatment mandate for health care workers being promulgated by the Biden administration will cause further attrition of staffing in rural hospitals,” he said.

€œThese CEOs support allowing weekly testing for hair loss treatment as an alternative to a treatment mandate.” But Dr propecia cheapest price. Nicole Rouhana with the Rural Nurse Organization, a nurse/midwife with a 40-year career in health care and program director at the State University of New York in Binghamton, said media reports of rural nurses becoming traveling nurses seem overblown. €œI think it’s gotten a lot of press, but I don’t think it’s as prevalent as everybody thinks it is,” she said. €œI mean, there are people who might have small children or they might want to go somewhere for two propecia cheapest price weeks and make a lot of cash and then come home to take care of their kids.

We are seeing it, but it’s not lasting long.” Rouhana said she felt the use of traveling nurses would begin to wane a bit when the country gets hair loss treatment under control, over the next two or three years. But by then, she said, propecia cheapest price the issue facing healthcare will be the increasing numbers of baby boomers aging and putting further strain on the healthcare system. Rural areas, whose residents tend to be older, poorer, and sicker, will need more nurses to care for them as they age. Already, healthcare organizations like RNO are working to propecia cheapest price recruit people into the nursing profession.

The key to getting nurses to stay long-term in rural areas, she said, was recruiting people who already live there. €œIf we develop our Healthcare Workforce from within the communities, where they come from, we’re going to propecia cheapest price have a long-term provider,” she said. €œThey raise their kids there. They were born and raised there.

They might propecia cheapest price have land there. So their likelihood of them staying there long-term is much higher than if, for instance, we recruited somebody from an urban setting to come to the rural area. Research shows that they (urban recruits) usually stay in a rural setting propecia cheapest price for only two to three years.” Other programs through the U.S order generic propecia. Office of Health Resources and Services Administration provide scholarships for two-year nursing programs in exchange for a two-year commitment to work in a rural area, she said.

Federal workforce grants are also available to provide students with tuition, laptops, clinical equipment and propecia cheapest price specialized training to care for rural populations, she said. €œWe can bypass all those recruitment and retention efforts that healthcare organizations are burdened with by, instead, doing focused recruitment from within our rural communities and saying to these nurses ‘Hey, you want to become a nurse practitioner?. I’ll pay you, you can do your training right in your community and then when you graduate, the people who trained you are probably going to want to hire you because you live in the community, you’re known and respected in the community and we trained you.’” You Might Also LikeCredit. Pixabay/CC0 Public Domain In the heart propecia cheapest price of a city, the distances in rural communities may be difficult to envision.

The space between neighbors can sometimes be measured in miles rather than blocks. A drive propecia cheapest price to the nearest hospital may take dozens of minutes rather than a handful. The trickle-down effect of such distances can impact many aspects of health care, but especially maternal care and delivery, says Mark Deutchman, MD, a professor of family medicine and associate dean for rural health at the University of Colorado School of Medicine.As principal investigator of a study recently published in the journal Birth analyzing the impact of family physicians in rural maternity care, Deutchman and his co-investigators found that of the 185 rural hospitals surveyed in 10 states, family physicians delivered babies in 67% of the hospitals and were the only physicians who delivered babies in 27% of them.Further, the study found that if family physicians stopped delivering babies in these rural hospitals, patients would have to drive an average of 86 miles round-trip to access maternal care."The purpose of this study was, number one, to understand the extent of family physicians providing maternity care in rural areas," Deutchman explains. "Number two, and even more important, was to understand what would happen to women if family practitioners did not practice propecia cheapest price maternity care, and that's the real take-home message.

Family physicians are really, really important."Study highlights importance of family physicians providing maternity careOn this topic, Deutchman speaks from experience. For more than 12 years he practiced family medicine in White Salmon, Washington, a town of 2,000 propecia cheapest price residents on the Columbia River. The local hospital is federally designated critical access, which means it has fewer than 20 beds, among other standards."One of the major things I was involved in was maternity care," he says. "I had a lot of OB patients and did a lot of deliveries.

I was also one of the major providers of surgical OB, of C-sections when they were needed."I'm an advocate for and student of the quality of outcomes in areas where family propecia cheapest price physicians are a woman's provider of obstetric and gynecologic care. I think that women deserve to have excellent care no matter where they are and no matter who provides it." After leaving rural practice, Deutchman became a faculty member at the University of Tennessee-Memphis, where he helped train family medicine residents for rural practice. He continued that focus after joining the University of Colorado propecia cheapest price School of Medicine in 1995. In 2005, he founded the school's rural track, which this year became a full-fledged program.His recently published research evolved from previous, similar studies he conducted in Colorado and Montana with medical students."It wasn't a study of quality—we weren't looking at individual cases and weren't looking at outcomes—but we wanted to better understand how much and the sort of maternal care family physicians are providing at rural hospitals," he explains.After refining the survey tool used in the previous studies, Deutchman reached out to colleagues across the country.

Those who responded represented 10 propecia cheapest price states and collected data about rural and frontier hospitals in their states. They gathered data about the hospitals' obstetrics capacity, who delivers babies at the hospitals and what their specialty is, and other data."Ultimately, we were looking at how important is it for family physicians to provide maternity care and what would access be if they didn't?. " Deutchman says.Rural program provides specialized training needed for medical students and residentsThe study's results, Deutchman says, highlight the importance of comprehensive, specialized training for medical students and residents who are interested in practicing in rural communities."Basically, the rural program is a way to attract, admit and support medical students and physician assistant students who want to live and work in rural areas when they finish their training," he explains. "We need to have a program so that people who are interested in rural practice will have their aspirations supported and also have a way to test their assumptions about rural practice and see if it's really right propecia cheapest price for them."The last thing we want is for students to have romanticized ideas, and then they show up in a small town and it wasn't what they had in mind.

We also don't want to have that revolving door where physicians go to a small community for only two or three years, which fosters distrust and a lack of attachment between doctors and the community."Through the rural program, students not only receive on-campus experience in the classroom and clinical training, but they get significant rural clinic experience with partners throughout Colorado. That aspect of the training is vital, Deutchman says, because students learn in-person about rural health care systems and economics, community engagement, health care ethics, and how to practice in a community where physicians might regularly see patients at the grocery store.Since 2005, Deutchman says, 191 students in the CU School of Medicine have graduated in the propecia cheapest price rural track, 40% of whom concentrated on family medicine."A common question is, 'How do you get people interested in rural practice and providing care like delivering babies?. '" Deutchman says. "Partly, we start out with people who are initially interested, then we help nurture that interest with real facts and real practical experience."Basically, the whole state of Colorado is short of primary care, especially propecia cheapest price in rural areas, which cannot support one of every kind of sub-specialist.

Rural communities need versatile, broadly-trained and skilled physicians who can share clinical responsibilities with each other to avoid burnout. Family physicians can provide acute care, chronic care, end of life care, deliver babies, put on casts, repair lacerations—in the most accessible, cost-effective fashion. It's vital we train and support these physicians who go out and support these rural communities." Explore further propecia cheapest price Finding a doctor is tough and getting tougher in rural America More information. Mark Deutchman et al, The impact of family physicians in rural maternity care, Birth (2021).

DOI. 10.1111/birt.12591 Provided by CU Anschutz Medical Campus Citation. Study finds family physicians deliver babies in majority of rural hospitals (2021, October 19) retrieved 22 October 2021 from https://medicalxpress.com/news/2021-10-family-physicians-babies-majority-rural.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission.

The content is provided for information purposes only..

Generic drug for propecia

IntroductionSOX10 belongs to the SOX family of transcription more helpful hints factors, of which the members are generic drug for propecia defined based on the presence of a 79 amino acid DNA-binding domain with homology to the high mobility group (HMG) box of SRY (sex-determining region Y. Hence SOX, Sry bOX). These factors are involved in multiple developmental processes, such as male differentiation, skeletogenesis, neurogenesis and neural crest (NC) development, where they control stemness, cell fate and differentiation.1–4 The growing number of developmental disorders associated with mutations in SOX genes underscores their importance during development.5 The SOX10 transcription factor is a characteristic marker for migratory multipotent NC progenitors as well as for various NC derivatives.The NC is a specific population of cells in vertebrates that arise at the edge between the neural and non-neural ectoderm, delaminate from the dorsal aspect of the neural tube, and migrate through several routes to reach target tissues and give rise to neurons and glia of the peripheral nervous system (PNS), including sensory, autonomous and enteric ganglia, Schwann cells and olfactory ensheathing cells, melanocyte pigment cells, skeletal generic drug for propecia structures and mesenchyme of the head, face and neck, outflow tract of the heart, and smooth muscle cells of the great arteries.6 7Over the years, heterozygous SOX10 mutations have been associated with various phenotypes that extend beyond Waardenburg syndrome (WS.

Depigmentation features and deafness) and Hirschsprung disease (HSCR. Intestinal aganglionosis) initial diagnosis. Here, we present an up-to-date overview of these various clinical manifestations, along with our current understanding of how they are explained by SOX10 dysfunction in generic drug for propecia several NC derivatives and extra-NC tissues (inner ear and oligodendrocytes), and of the origin of phenotypic variability.SOX10.

Structure and regulation of the gene, protein domains and post-transcriptional modificationsThe human SOX10 and mouse Sox10 genes encode an open reading frame of 466 amino acids that share 92% nucleotidic and 98% amino acid sequence identities.8 The absence of a complete description of the human gene 5’ non-coding exon(s) has given rise to two coexisting exon numbering systems. Historically, exons 1 and 2 are non-coding, the initiation codon is found in exon 3, and the stop codon in exon 5.8 The second system is based on the reference transcript NM_006941, with only one non-coding exon in the 5’UTR (untranslated transcribed region) and a total of four exons. A major transcript generic drug for propecia of ~3 kb is detected in most tissues tested, consistent with the predicted SOX10 mRNA sequence.9 10The protein’s structure is schematised in figure 1.

As for all other members of the SOX family, the previously mentioned HMG domain forms an L-shaped module composed of three alpha helices that bind to DNA sequences in the minor groove (matching or resembling C[A/T]TTG[A/T][A/T]), bending the DNA molecule and interacting with other proteins to establish stable and active transcriptional complexes3 4 (the most recent model can be found in Haseeb and Lefebvre11). This domain also harbours two nuclear import (nuclear localisation signal) and one export (nuclear export signal) signals.12 1310 samples in various tissues (including the brain, gut, nerves (tibial), breast and salivary glands)/total number of A-to-I modifications reported is. AluY.

20/73. DIM, dimerisation domain. ERK, extracellular signal-regulated kinase.

HMG, high mobility group domain. NES, nuclear export signal. NLS, nuclear localisation signal.

TA/TAC, transactivation domain in C-terminal. TAM, transactivation domain in the middle of the protein." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-2069966281" data-figure-caption="Schematic of the SOX10 protein and post-translational modifications. Domains of human SOX10.

The numbers refer to amino acid residues. The pink lines above the HMG domain represent the NLS sequences, one at each end of the HMG domain, and the light pink line the NES sequence. Note that although nucleocytoplasmic shuttling of the protein has been well documented for several SOX factors,12 13 in vivo regulation of SOX10 through nuclear translocation is yet to be clarified.

Black arrowheads represent the localisation of junctions between exons. Post-transcriptional modifications, including acetylation (Ac), phosphorylation (P) and sumoylation (Su), are indicated, along with the position of modified amino acids. Note that a putative acetylation site was identified in SOX2 and is conserved in SOX10.17 Sumoylation by Ubc9 occurs at lysines K55, K246 and K357 with consequences on cell fate decision.19 20 Mechanistically, sumoylated SOXE proteins fail to interact with the coactivator CBP (CREB-binding protein)/p300 and instead recruit the GRG4 corepressor (Groucho-related protein 4/TLE4, transducing-like enhancer of split 4), leading to strong inhibition of SOXE target genes.106 Among the identified phosphorylation sites, note that ERK phosphorylates T240 and T244, inhibiting the sumoylation of SOX10 at K55 and transcriptional activity.107 Additional phosphorylation sites have been described from large-scale proteomic screens in melanoma, breast tumours and mouse neuroblastoma (serine S8, S13, S17, S24, S27, S30, S40, S45, S221, S224 and S23216).

The relevance of most has not been functionally assessed. SOX10 phosphorylation sites are localised in two distinct clusters, one at the amino terminus, 5’ of the dimerisation domain, and the other at the centre of the protein. FBXW7-mediated ubiquitination of SOX10 has also been shown to control protein stability.

The region involves aa 235–244 of the human protein. A search of the public REDIportal (http://srv00.recas.ba.infn.it/atlas/) revealed various A-to-I editing sites located in AluY, AluSx or AluSq sequences embedded in the last SOX10 intron. In each Alu sequence schematised from left to right, the number of A-to-I sites identified in >10 samples in various tissues (including the brain, gut, nerves (tibial), breast and salivary glands)/total number of A-to-I modifications reported is.

ERK, extracellular signal-regulated kinase. HMG, high mobility group domain. NES, nuclear export signal.

NLS, nuclear localisation signal. TA/TAC, transactivation domain in C-terminal. TAM, transactivation domain in the middle of the protein." data-icon-position data-hide-link-title="0">Figure 1 Schematic of the SOX10 protein and post-translational modifications.

Domains of human SOX10. The numbers refer to amino acid residues. The pink lines above the HMG domain represent the NLS sequences, one at each end of the HMG domain, and the light pink line the NES sequence.

Note that although nucleocytoplasmic shuttling of the protein has been well documented for several SOX factors,12 13 in vivo regulation of SOX10 through nuclear translocation is yet to be clarified. Black arrowheads represent the localisation of junctions between exons. Post-transcriptional modifications, including acetylation (Ac), phosphorylation (P) and sumoylation (Su), are indicated, along with the position of modified amino acids.

Note that a putative acetylation site was identified in SOX2 and is conserved in SOX10.17 Sumoylation by Ubc9 occurs at lysines K55, K246 and K357 with consequences on cell fate decision.19 20 Mechanistically, sumoylated SOXE proteins fail to interact with the coactivator CBP (CREB-binding protein)/p300 and instead recruit the GRG4 corepressor (Groucho-related protein 4/TLE4, transducing-like enhancer of split 4), leading to strong inhibition of SOXE target genes.106 Among the identified phosphorylation sites, note that ERK phosphorylates T240 and T244, inhibiting the sumoylation of SOX10 at K55 and transcriptional activity.107 Additional phosphorylation sites have been described from large-scale proteomic screens in melanoma, breast tumours and mouse neuroblastoma (serine S8, S13, S17, S24, S27, S30, S40, S45, S221, S224 and S23216). The relevance of most has not been functionally assessed. SOX10 phosphorylation sites are localised in two distinct clusters, one at the amino terminus, 5’ of the dimerisation domain, and the other at the centre of the protein.

FBXW7-mediated ubiquitination of SOX10 has also been shown to control protein stability. The region involves aa 235–244 of the human protein. A search of the public REDIportal (http://srv00.recas.ba.infn.it/atlas/) revealed various A-to-I editing sites located in AluY, AluSx or AluSq sequences embedded in the last SOX10 intron.

In each Alu sequence schematised from left to right, the number of A-to-I sites identified in >10 samples in various tissues (including the brain, gut, nerves (tibial), breast and salivary glands)/total number of A-to-I modifications reported is. AluY. 67/224.

DIM, dimerisation domain. ERK, extracellular signal-regulated kinase. HMG, high mobility group domain.

NES, nuclear export signal. NLS, nuclear localisation signal. TA/TAC, transactivation domain in C-terminal.

TAM, transactivation domain in the middle of the protein.SOX10 shares additional domains with SOX8 and SOX9, all three forming the SOX_E group (SOX factors have been subdivided in several groups based on the amino acid identity within their HMG domain) (figure 1). Among them, the dimeric domain (DIM) confers preferential binding of SOX_E members to target sites containing two inverted SOX motifs separated by three to four nucleotides and promotes homodimerisation or heterodimerisation through DIM:HMG interactions.14Within its C-terminus, SOX10 contains a potent transactivation domain called the TA or TAC (transactivation domain in C-terminal).4 Another weaker and context-dependent transactivation domain has been identified in the middle of SOX10, the so-called K2 domain or TAM (transactivation domain in the middle of the protein), and was recently shown to synergise with TA/TAC in all SOX_E members.11 15Various post-transcriptional and post-translational modifications modulate the activity, stability and intracellular localisation of SOX1016 (figure 1). Several of these modifications are inferred from those occurring in other SOX factors, as for the lysine K136 acetylation site.16–18 Others, including phosphorylation sites, were mainly found from large-scale proteomic screens performed in cancer cells.

SOX10 sumoylation by UBC9 (sumo-conjugating enzyme UBC9) is the best described one. Occurring at lysines K55, K246 and K357,19 it inhibits NC development and promotes development of non-sensory cranial placodes in vivo.20 Absence of A-to-I RNA modification mediated by the ADAR (adenosine deaminase RNA-specific) enzyme family was recently reported to alter melanocyte and Schwann cell development.21 Examination of the public REDIportal shows that SOX10 is under such regulation in humans (but not mice).Finally, several regulatory regions likely involved in driving SOX10/Sox10 expression have been identified using various cell lines and zebrafish or mice models (ref 22 and references therein). Methylation of the Sox10 promoter by DNA methyansferase 3 has also been shown to arrest NC generation in chicks.23Involvement of SOX10 in WS.

Role in melanocytes and enteric nervous systemThe identification of Sox10 as the gene mutated in the spontaneous Dom mutant mouse (Dominant megacolon. Intestinal aganglionosis, white belly spot and white paws) first shed light on the essential function of this transcription factor in NC development. In this strain, a Sox10 frameshift mutation results in alteration of binding to some DNA target sequences in vitro, of transactivation capacity and synergistic action with several cofactors.9 24–27 This observation immediately led to test SOX10 involvement in Waardenburg-Hirschsprung disease.8 Also known as WS type 4 (WS4) or Waardenburg-Shah syndrome, Waardenburg-Hirschsprung encompasses symptoms of WS and HSCR (Mendelian inheritance in man, MIM) #613266).28–30HSCR is the most common enteric neuropathy, occurring in 1 of 5000 neonates, and is characterised by the absence of enteric ganglia from a varying length of the distal gut, leading to intestinal obstruction in neonates or severe constipation in adults (MIM #142623).29 30WS is a genetic disorder characterised by sensorineural hearing loss (SNHL) and pigmentation anomalies, including depigmented patches of skin and hair and vivid blue eyes or iris heterochromia (MIM #193500).

Four types of WS are clinically defined, based on additional features due to defects in structures mostly arising from NC derivatives. WS1 is further characterised by dystopia canthorum, WS3 by musculoskeletal abnormalities of the limbs, WS4 by HSCR, whereas WS2 has no further significant features. In addition to SOX10, four main genes are involved in WS thus far.

MITF (melanocyte inducing transcription factor) in WS2, PAX3 (transcription factor paired Box 3) in WS1 and WS3, EDN3 (endothelin 3) in WS4, and EDNRB (endothelin receptor type B) in WS4 and WS2.28 31 32 SOX10 has been shown to regulate and interact with several of these genes.28 33SOX10 screening in WS4 cases led to the identification of the first heterozygous mutations in 1998.8 In 2007, SOX10 mutations were shown to be also responsible for approximately 15% of WS2 cases.34 By contrast, SOX10 involvement in isolated HSCR is very limited. For example, screening of 229 isolated HSCR cases led to the identification of only one frameshift mutation inherited from an asymptomatic mother (germline mosaicism has been proposed).35Certain patients with WS4 or PCWH (see later) present with hypoganglionosis or chronic intestinal pseudo-obstruction (CIPO) instead of HSCR.28 36–39 Given the role of SOX10 in enteric nervous system (ENS) development, CIPO is probably neurogenic. Aganglionosis is therefore not the only mechanism underlying the intestinal dysfunction in patients with SOX10 mutations.Each of the clinical manifestations described above can be explained by dysregulation of SOX10 during melanocyte and ENS development.

WS accounts for a developmental defect in both skin melanocytes and a melanocyte-derived cell lineage of the inner ear, called intermediate cells of the stria vascularis, necessary to the inner ear homeostasis.40 In melanocytes, SOX10 controls proliferation, survival and differentiation by directly and sequentially activating a number of downstream target genes.4 41–43 From the NC, a SOX10–PAX3 pair activates the expression of Mitf/MITF, which then acts as a SOX10 partner to activate the expression of Dct (dopachrome tautomerase) and Tyr (tyrosinase), both involved in melanocyte differentiation and melanin synthesis.27 32 42 44 45 In 2015, an extensive genome-wide catalogue of SOX10 targets was obtained.46 For the first time, integrated chromatin occupancy and transcriptome analysis suggested a role of SOX10 in both transcriptional activation and repression. SOX10 was also shown to cooperate with MITF to facilitate BRG1 (Brahma-related gene 1/SMARCA4, SWI/SNF related, matrix associated, actin-dependent regulator of chromatin) binding to distal enhancers of melanocyte-specific genes, promoting differentiation.47In the developing gut, SOX10 is expressed in all NC-derived ENS progenitors.22 24 48–50 Later, SOX10 is maintained in enteric glia but downregulated in cells that are committed to neurons (see refs 25 50 for examples). Most publications suggest a role of SOX10 in the maintenance of enteric progenitors,22 49 and overexpression of SOX10 inhibits enteric neuron differentiation, without altering commitment to the neurogenic lineage.25 51 These cellular functions rely on the capacity of SOX10 to regulate (along with several cofactors) various target genes, including Ret (RET proto-oncogene.

A receptor tyrosine kinase involved in ENS development and the main HSCR-related gene), Ednrb and Sox10 itself.22 33 52 53 As an example SOX10 and ZEB2 (zinc-finger E-box binding homeobox 2. A negative regulator of NC differentiation) both bind to Ednrb promoter-specific regions, highlighting the role of this ‘triade’ in controlling the maintenance of multi-potential enteric progenitors and their differentiation process.33Hearing loss associated with SOX10 mutations. Beyond melanocytes, SOX10 expression in inner ear and related deficitsSNHL due to SOX10 mutations, as for the other WS genes, is typically prelingual, non-evolutive, profound and bilateral.

However, it can also be moderate and asymmetric or unilateral.Aside from the intermediate-cell alterations mentioned above, inner ear malformations have been noted in some patients with WS long ago.54 It now appears that only patients with a SOX10 mutation present with these abnormalities. Hypoplasia/dysplasia or agenesis of the semicircular canals and enlarged vestibules are very frequent, while agenesis of the vestibulo-cochlear nerve and cochlear deformities have also been reported.55–57 Consequently, temporal CT scan or MRI is of particular interest in diagnosis. In our experience, this feature is highly penetrant when interpreted by a specialised radiologist.

However, recent papers reported the absence of imaging abnormalities in the inner ear of a few patients with SOX10 mutations. A complete exploration of the vestibular function has yet to be performed.These observations are consistent with an expression profile of Sox10 in the ear. Sox10 is expressed in the placode-derived otic vesicle from E9.5 onward and then in the developing epithelium of the cochlea and vestibule, before being restricted to supporting cells of the neurosensory epithelium.

Sox10/SOX10 promotes the survival of cochlear progenitors during formation of the otocyst and the organ of Corti, plays a role in glial development of the cochleovestibular ganglia, and its NC-targeted deletion leads to improper neuronal migration and projection.58–60 The resulting inner ear malformations differ depending on the animal model.58 61 62 RNA-seq studies of inner ear development in a pig model showed dysregulation of WNT1 (Wnt family member 1. A regulator of cell fate and patterning), KCNQ4 (potassium voltage-gated channel subfamily Q), STRC (stereocilin. A protein associated with the hair bundle of the ear sensory cells) and PAX6 (transcription factor Paired Box 6) networks.62In agreement with this broad function, SNHL appears to be the most penetrant sign in cases of SOX10 mutation, leading to the observation that certain patients can present with isolated SNHL until minor signs are revealed on medical reinterview.63PCWH and PCW phenotypes.

Important function of SOX10 in Schwann cells and oligodendrocytesBeyond WS2 or WS4, neurological alterations have been identified in the so-called PCWH syndrome (peripheral demyelinating neuropathy, central dysmyelinating leukodystrophy, Waardenburg syndrome, Hirschsprung disease. MIM #609136).28 36 64 Depending on the severity of myelin defects in the PNS and central nervous system (CNS), patients with PCWH exhibit variable symptoms that often include delayed motor and cognitive development, cerebral palsy, ataxia, spasticity, congenital nystagmus, hyporeflexia, distal sensory impairments and distal muscle wasting. This phenotype is recapitulated in a transgenic mouse model with several copies of SOX10 carrying the first PCWH mutation described65 66 and is mostly explained by the role of SOX10 during differentiation of myelinating Schwann cells and oligodendrocytes, both ensuring rapid salutatory conduction along axons.67 68In the PNS, SOX10 controls each differentiation step by inducing stage-restricted transcriptional regulators, which are then recruited as partners to activate specific sets of target genes, allowing progression to the next stage.67–72 For example, in immature Schwann cells, SOX10 induces the expression of OCT6 (POU3F1, POU class 3 homeobox 1).

Both factors then cooperatively activate the programme required for progression into the promyelinating stage. Their target EGR2 (early growth response 2) then associates with SOX10 to activate the myelination programme.In the CNS, analyses of various animal models revealed an essential role of SOX10 in the terminal differentiation of oligodendrocytes in coordination with OLIG1 (OLIGodendrocyte transcription factor 1), MYRF (myelin regulatory factor), TCF4 (transcription factor 4, which has an important role in CNS development) and CHD7 (chromodomain helicase DNA-binding protein 7. The gene involved in CHARGE syndrome (Coloboma, Heart anomaly, choanal Atresia, Retardation, Genital and Ear anomalies)).68 Many genes that are activated during terminal differentiation of oligodendrocytes are direct targets of SOX10, but there are only few known SOX10 targets in oligodendrocyte precursors.68 73 74 Recently, MYRF was identified as a decisive factor that helps SOX10 to switch between its target genes along oligodendrocyte differentiation process.75Of interest, some of the genes directly regulated by SOX10 in PNS and CNS are known to be responsible for hypomyelinating/demyelinating diseases, with some described mutations in these genes that directly result from a loss of regulation by SOX10.76–78Involvement of SOX10 in Kallmann syndrome and its role in olfactory ensheathing cellsSOX10 was considered to be a candidate gene for Kallmann syndrome (KS, hypogonadotropic hypogonadism and anosmia.

MIM #308700) based on the unexpected high frequency of olfactory bulb agenesis55 associated with rare clinical reports of hypogonadism or anosmia in patients with WS/PCWH with a SOX10 mutation. The screening of cohorts indeed revealed SOX10 mutations in patients with KS, most of whom also have hearing impairment.79 Since then, many other SOX10 mutations have been characterised in KS or normosmic idiopathic hypogonadotropic hypogonadism (nIHH), although they were usually not functionally characterised and a subset of them appeared unlikely to be pathogenic (see Review of SOX10 variations). Interestingly, KS and WS are not mutually exclusive, and some patients with an initial diagnosis of WS have been further diagnosed with hypogonadism at puberty.80 We believe that anosmia and hypogonadism are still underestimated in patients with WS with a SOX10 mutation, as signs of KS are difficult to diagnose before puberty.

Of note, in the absence of pigmentary disturbances, the association of KS+hearing impairment+abnormalities of the semicircular canals can lead to a differential diagnosis with mild forms of CHARGE syndrome (MIM #214800) (examples in online supplemental table 1).Supplemental materialThe common cause of anosmia and hypogonadism is a defect in a developmental sequence of GnRH (gonadotropin-releasing hormone) neurons migrating along the peripheral olfactory nerve up to and through the olfactory bulb. In the Sox10 knockout mouse, a primary defect of the olfactory ensheathing cells leads to a secondary defect of the olfactory nerve pathway, defasciculation and misrouting of the nerve fibres, impaired migration of GnRH cells along this route, and disorganisation of the olfactory nerve layer of the olfactory bulbs.79 Dysregulation of the frizzled related protein FRZB may contribute to explain the defect in olfactory axon targeting but not GnRH neuron migration.81A summary of the recurrent clinical manifestations due to constitutive SOX10 mutations along with affected cell types is presented in figure 2.Summary of the clinical spectrum due to SOX10 mutations and the corresponding SOX10 function(s). The picture is organised around three clinical poles that correspond to different diagnosis entries.

The WS pole is indicated in red, the myelin pole in blue and the KS pole in green. The plain line corresponds to the definition of the disease, while the dotted lines indicate the main clinical extension of these syndromes in case of SOX10 mutation. Note that the area of the circles is not proportionate to the relative frequency of each syndrome (for an idea about the number of patients, see figure 3B).

CIPO, chronic intestinal pseudo-obstruction. CNS, central nervous system. ENS, enteric nervous system.

GnRH, gonadotropin-releasing hormone. HSCR, Hirschsprung disease. KS, Kallmann syndrome.

NIHH, normosmic idiopathic hypogonadotropic hypogonadism. PCWH, peripheral demyelinating neuropathy, central dysmyelination, Waardenburg syndrome, with Hirschsprung disease. PNS, peripheral nervous system.

SNHL, sensorineural hearing loss. WS, Waardenburg syndrome. WS2, Waardenburg syndrome type 2.

WS4, Waardenburg syndrome type 4." data-icon-position data-hide-link-title="0">Figure 2 Summary of the clinical spectrum due to SOX10 mutations and the corresponding SOX10 function(s). The picture is organised around three clinical poles that correspond to different diagnosis entries. The WS pole is indicated in red, the myelin pole in blue and the KS pole in green.

The plain line corresponds to the definition of the disease, while the dotted lines indicate the main clinical extension of these syndromes in case of SOX10 mutation. Note that the area of the circles is not proportionate to the relative frequency of each syndrome (for an idea about the number of patients, see figure 3B). CIPO, chronic intestinal pseudo-obstruction.

CNS, central nervous system. ENS, enteric nervous system. GnRH, gonadotropin-releasing hormone.

HSCR, Hirschsprung disease. KS, Kallmann syndrome. NIHH, normosmic idiopathic hypogonadotropic hypogonadism.

PCWH, peripheral demyelinating neuropathy, central dysmyelination, Waardenburg syndrome, with Hirschsprung disease. PNS, peripheral nervous system. SNHL, sensorineural hearing loss.

WS, Waardenburg syndrome. WS2, Waardenburg syndrome type 2. WS4, Waardenburg syndrome type 4.Involvement in cancer, sex reversal, associations and reports of the first biallelic mutationsBeyond congenital disorders, a role of SOX10 in cancer progression has been reported.

SOX10 protein is highly expressed in breast, glioma, glioblastoma, salivary adenoid cystic tumours and hepatocellular carcinoma (see The Cancer Genome Atlas). The association of SOX10 with melanoma is the best described, but only a limited number of variants have been reported so far.82–84Several reports of duplications in the 22q13.1 region have been published that may include one or several signs of WS/PCWH and sex reversal in a number of cases.85 Sex reversal has been suggested to be due to the overexpression of SOX10, consistent with observations in a Sox10 transgenic mouse model.86 However, we found a SOX10 triplication (four doses of SOX10 instead of two) in a 47,XX baby girl without sex reversal (online supplemental table 1), indicating that overexpression of SOX10 alone may not be sufficient, the sign is not fully penetrant or the overexpression of other genes has the opposite effect, depending on the size of the rearrangement.More complex and questionable associations have also been described. For example, increased DNA methylation of SOX10 has been linked to oligodendrocyte dysfunction in patients with schizophrenia.87Two cases of biallelic SOX10 deletion have been characterised and, although not reported in the papers, they appear to represent the first and second pregnancy from the same couple.88 89 Both parents are heterozygous for one of the two SOX10 deletions and present with a classic form of WS.

Biallelic SOX10 loss-of-function results in a severe polymalformative fetal phenotype. Eighteen other genes were included in the maternal deletion and may participate in the phenotype.Finally, the development of large gene panels for diagnosis and whole exome/whole genome sequencing has led to SOX10 mutations being found in unexpected contexts. A number of cases have thus been listed in cohorts of neurodevelopmental defects, hearing impairment and endocrinological problems.

Due to the diverse phenotypes related to SOX10 mutations, making sense of such findings can be challenging.Review of SOX10 variationsDuring the first 15 years after their discovery, most SOX10 disease-associated point mutations were shown to result in premature termination codons, with strikingly few exceptions.28 Missense mutations started to be found simultaneously with the finding that SOX10 mutations can cause less severe syndromes than life-threatening WS4 or PCWH.90An up-to-date summary of confident mutations of SOX10 (approximately 300 independent cases, including unpublished ones in online supplemental table 1) is presented in figure 3A. Truncations (stops, frameshifts) are found in slightly more than half of all cases. Approximately one-third of all mutations are non-truncating variations, either missense or small inframe insertions/deletions, the rest being either complete or partial copy number variations of the gene (approximately 10%) and rare mutational mechanisms (splice mutations, mutation of the initiation codon or non-stop mutations (five cases to date)).

Truncating mutations can be located anywhere, except in the very extreme C-terminus. On the contrary, missense mutations are tightly clustered in the DNA-binding domain (HMG), a frequent finding for transcription factors. We have thus far found no specific link between SOX10 missense mutations and residues involved in post-translational modifications.Review of SOX10 mutations.

(A) Representation of SOX10 truncating and non-truncation mutations along the SOX10 protein. We made a list of all published SOX10 mutations, starting with the LOVD database that we curated up to 2015 (https://databases.lovd.nl/shared/genes/SOX10), updated with the literature and finally completed using the HGMD (Human Gene Mutation Database) professional database (https://digitalinsights.qiagen.com/products-overview/clinical-insights-portfolio/human-gene-mutation-database) for a few mutations that were reported in cohorts of unspecific diagnosis and would have been missed by common keywords. We prioritised the strength of the data to create this figure, as our goal was not to include all cases but to provide a reliable picture of the SOX10 mutational spectrum.

We retained papers for which the data allowed curation and removed neutral variants and variants of unknown significance, duplicated patients or publications, and publications with inconsistent findings. Finally, we added our unpublished cases (listed in online supplemental table 1). €˜M1?.

€™ indicates a mutation of the initiation codon (p.Met1?. ). (B) Proportion (in percentage) of the different types of mutations for each syndrome.

€˜n’ indicates the number of independent cases included in each group. (C) Localisation of the truncating (stop and frameshift) mutations along the SOX10 protein associated with each phenotype. Note that (1) the phenotypic description was sometimes too incomplete for inclusion in B and C.

(2) among the familial cases showing intrafamilial differences in phenotype, we considered the phenotype of the index case. (3) KS/nIHH is given regardless of the presence of WS signs or not, and anosmia without hypogonadism was not considered. And (4) because presence or absence of a demyelination is frequently unreported or not evaluated, we conserved all the patients with neurological features in the PCW/PCWH group when the data seemed consistent.

DIM, dimeric domain. HMG, high mobility group. KS, Kallmann syndrome.

LOVD, Leiden OPen Variation Database. NIHH, normosmic idiopathic hypogonadotropic hypogonadism. PCW/PCWH, peripheral demyelinating neuropathy, central demyelination, Waardenburg syndrome, with or without Hirschsprung disease.

TA, transactivation domain in C-terminal. TAM, transactivation domain in the middle of the protein. WS, Waardenburg syndrome.

WS2, Waardenburg syndrome type 2. WS4, Waardenburg syndrome type 4." data-icon-position data-hide-link-title="0">Figure 3 Review of SOX10 mutations. (A) Representation of SOX10 truncating and non-truncation mutations along the SOX10 protein.

We made a list of all published SOX10 mutations, starting with the LOVD database that we curated up to 2015 (https://databases.lovd.nl/shared/genes/SOX10), updated with the literature and finally completed using the HGMD (Human Gene Mutation Database) professional database (https://digitalinsights.qiagen.com/products-overview/clinical-insights-portfolio/human-gene-mutation-database) for a few mutations that were reported in cohorts of unspecific diagnosis and would have been missed by common keywords. We prioritised the strength of the data to create this figure, as our goal was not to include all cases but to provide a reliable picture of the SOX10 mutational spectrum. We retained papers for which the data allowed curation and removed neutral variants and variants of unknown significance, duplicated patients or publications, and publications with inconsistent findings.

Finally, we added our unpublished cases (listed in online supplemental table 1). €˜M1?. €™ indicates a mutation of the initiation codon (p.Met1?.

). (B) Proportion (in percentage) of the different types of mutations for each syndrome. €˜n’ indicates the number of independent cases included in each group.

(C) Localisation of the truncating (stop and frameshift) mutations along the SOX10 protein associated with each phenotype. Note that (1) the phenotypic description was sometimes too incomplete for inclusion in B and C. (2) among the familial cases showing intrafamilial differences in phenotype, we considered the phenotype of the index case.

(3) KS/nIHH is given regardless of the presence of WS signs or not, and anosmia without hypogonadism was not considered. And (4) because presence or absence of a demyelination is frequently unreported or not evaluated, we conserved all the patients with neurological features in the PCW/PCWH group when the data seemed consistent. DIM, dimeric domain.

HMG, high mobility group. KS, Kallmann syndrome. LOVD, Leiden OPen Variation Database.

NIHH, normosmic idiopathic hypogonadotropic hypogonadism. PCW/PCWH, peripheral demyelinating neuropathy, central demyelination, Waardenburg syndrome, with or without Hirschsprung disease. TA, transactivation domain in C-terminal.

TAM, transactivation domain in the middle of the protein. WS, Waardenburg syndrome. WS2, Waardenburg syndrome type 2.

WS4, Waardenburg syndrome type 4.Of course, rarity in control populations is not sufficient to confer pathogenicity and the prediction of pathogenicity by dedicated tools is of indicative value only. Among the published SOX10 missense variations that are located outside of the HMG domain, most should be considered variants of unknown significance. From our experience and bibliography review, it appears that extremely rare or new missense variations have a high probability of being truly pathogenic if located in the HMG domain, whereas missense mutations located outside of this domain, even if rare and ‘predicted pathogenic’ by in silico tools, are less likely to be pathogenic and should be considered cautiously.

We have worked on SOX10 since its characterisation, both in the research and clinical context, and have only once found an exception to each of these rules. With the increasing number of mutations described, it appears that there may be a second, rare spot of mutations in the dimerisation domain (three variations reported in four independent cases, creating or removing valines at residues 76, 79 and 80), although functional tests are required to reach a definitive conclusion91 92 (online supplemental table 1).Due to the well-documented incomplete penetrance and digenism in KS and nIHH, there is a tendency in the literature to overevaluate the pathogenic probability of rare variants. Certain SOX10 variations have been considered to be pathogenic or likely pathogenic without many arguments (low pathogenicity scores, no functional tests, proven not pathogenic in another paper, inherited from healthy parents or without segregation study, and/or associated with an obvious causative mutation in another KS/nIHH gene).

On careful review, we consider several of these rare missense variants to more likely be neutral (although some still may be hypomorphic variants exerting their effect on a multigenic background, but this has thus far not been proven) and did not include them in figure 3.In early studies, most SOX10 variants were found to be de novo, which was thought to be due to the severity of HSCR in WS4. Given the cumulative number of WS2 cases now described, the life-threatening hypothesis cannot completely explain the proportion of de novo mutations. The possibility of hypogonadism in patients probably also contributes to this observation.

However, the proportion of familial cases has tended to increase over the years and now represents approximately 20% of cases. These cases revealed an important intrafamilial phenotypic variability. Several mutations have now been found in independent cases and also show interfamilial phenotypic variability.

Parental mosaicism is found in approximately 3%–4% of cases, but a recent study reported a higher proportion in a small series using more sensitive methods.93The proportion of mutations relating to phenotype is summarised in figure 3B. There is a large proportion of truncating mutations in WS4 and PCWH. The proportion of missense increases in WS2 and even more strongly in KS.

Thus, not all missense mutations may be null mutations.The location of truncating mutations along the gene (figure 3C) confirms the correlation between PCWH and the escape from non-sense-mediated RNA decay (NMD) (mutations located in the last coding exon and last 45 nt of the penultimate exon).64 Of note, some of the cases that appear not to respect the NMD rule may be misclassified (whether demyelination is proven or not is not always reported). The severity of PCWH was shown to be linked to the location of the mutation within the last exon. The earlier the truncation, the more severe the phenotype.64 This tendency is visible in the graphs (compare the truncating mutations of WS vs PCWH in the last exon).

A few cases escape the rule, with no clear explanation so far.Finally, heterozygous deletions/duplications can be intragenic or lead to complete gene loss and be as large as several Mb, encompassing other genes and leading to more complex phenotypes.Functional consequences of SOX10 mutations and the origin of phenotypic variabilityMost in vitro functional tests found in the literature rely on the ability of SOX10 to activate its target genes, alone or in combination with its cofactors. The construct most frequently used is a luciferase reporter under the control of the MITF-M (melanocyte-specific isoform) promoter. Additional targets, immunohistochemistry and assessment of the contribution of the DNA-binding capabilities have sometimes enriched such studies.Functional analysis of the first SOX10 missense mutation suggested that differential tissue-specific gene regulation could account for the phenotype observed in patients.94–96 Since, many SOX10 missense mutations associated with a variety of phenotypes, ranging from WS2 to WS4 and PCWH, have been tested, but no clear correlation between in vitro results and the phenotypes could be established.79 90 97The development of in vivo tests is therefore required to facilitate the establishment of genotype–phenotype correlations.

The only model currently published is in ovo chick electroporation in the developing neural tube.26 However, the effect of most of the mutations on early NC development precludes the analysis of their role in later developmental processes. Use of an inducible model would be of interest. Alternatively, zebrafish or the use of induced pluripotent stem cells differentiated towards NC derivatives of interest could be future models of choice.As mentioned earlier, the presence or absence of a neurological phenotype that characterises PCWH or PCW was proposed to be related to NMD.64 The proposed mechanism is that mutant proteins that have escaped degradation via the NMD pathway result in dominant-negative activity that impairs the function of the wildtype SOX10 allele and lead to PCWH, while those located in the first coding exons activate the NMD RNA surveillance pathway, leading to degradation, haploinsufficiency and a classic WS phenotype.However, several non-stop mutations have also been described to be associated with a PCW/PCWH phenotype.

This is thought to be due to the generation of a specific inframe new C-terminus generated by the loss of normal termination. Functional studies of an equivalent mouse mutant allele showed that the additional 82 amino acids contain a deleterious (tryptophan-arginine (WR) domain, supporting a toxic gain-of-function.98 This is consistent with the recent report of a frameshift mutation that also elongates the protein, but in a different reading frame does not lead to PCWH (p.Tyr460Leufs*42).99 The observation of another, transgenic mouse model carrying different copy number variations of the first described SOX10 non-stop mutation suggested PCWH is due to a dominant-additive, rather than dominant-negative, effect.66 Finally, duplication of the 22q13.1 region, including SOX10, can also induce PCWH,85 supporting the hypothesis that it is promoted by a gain-of-function rather than a dominant-negative effect. Regardless of the mechanism, these observations all indicate that NC derivatives are highly sensitive to the dose of SOX10 and its function.SOX10 expression is regulated by numerous enhancers.

It is thus possible that certain cases with minor expression could also be due to specific dysregulation of one or a subset of such enhancers. This paradigm is supported by disruption of tissue-specific, long-distance regulatory regions of SOX9 causing endophenotypes.100 101 A large de novo deletion encompassing three SOX10 regulatory elements has been characterised in a patient with typical WS4,102 leading to the hypothesis that variations affecting certain identified regulatory sequences could be the cause of unexplained WS2 or isolated HSCR. Screening for mutations in SOX10 regulatory regions in WS2 turned out to be unfruitful.103 On the contrary, one deletion and two point variations affecting binding sites for known NC transcription factors were identified in 3 of 144 cases of isolated HSCR, both variations being in association with a HSCR-predisposition polymorphism at the RET locus.104 With the implementation of population databases, it now appears that one of these two variants is less rare than expected (22-38016774 G-C.

About 1/1000 according to the gnomAD database. Https://gnomad.broadinstitute.org/), which questions its involvement. These results are yet to be replicated for a pertinent interpretation.In any case, in vitro/in vivo tests will not be able to explain all phenotypes, as phenotypic variability is commonly recognised in patients with SOX10 mutations, even those with the same mutation and even within the same family.

This suggests that the genetic background is influential, as has often been suggested for HSCR.53 105 Because the identification of modifier genes has been hampered by the small number of available patients, most modifier gene studies have relied on Sox10 mouse models.22Despite such variability, certain specificities have been reported for a few peculiar missense mutations. Here, we want to discuss the case of the Gln174/Pro175 missense mutations. The observation that certain SOX10 missense mutants accumulate in nuclear foci in transfected cells, where they colocalise with p54NRB (nucleo ribo binding protein, 54 kDa/NONO, non-Pou domain containing octamer binding.

A multifunctional protein known to be a marker of ‘paraspeckles’), leads to characterise missense mutations of amino acids 174 and 175 as associated with a peculiar phenotype (refs 79 97 and unpublished data (S. Marlin, N. Bondurand and V.

Pingault, 2016)). Remarkably, the cotransfection of foci-forming mutant with wildtype constructs led to the sequestration of wildtype SOX10 in these ‘foci’ and altered the synergistic activity of SOX10 and p54NRB. A dominant-negative effect was therefore proposed to contribute to or be at the origin of the progressive central and peripheral neurological phenotypes observed in patients carrying these specific missense mutations and may thus be the basis of a hitherto unexplored molecular mechanism for genotype–phenotype correlations.

These data need to be confirmed in more physiological models.The phenotype variability finally leads to question the risk of a more severe phenotype in cases of recurrence in a family. The risk of the PCWH phenotype after a first non-PCWH case is considered to be low. On the contrary, there is a risk of WS4 after a first, milder case of WS2.

This situation has been reported several times. However, a bias in the representation of these cases in the literature can be expected, as a second mildly affected member is less likely to result in a visit of the family to the geneticist’s office, molecular analysis and ultimately publication. As a result, the true risk is difficult to quantify.Conclusion, with a few tips to help in variant classificationDuring twenty years of cases and cohorts reporting, SOX10 variants have been involved in WS2/WS4/PCWH/Kallmann syndrome/pseudo-isolated hearing loss/HSCR or CIPO and any combination.

This is correlated with the known developmental functions of SOX10. All these phenotypes should be considered as a clinical continuum with variable expression, rather than as independent diseases, conferring a mild to life-threatening syndrome. Observation of the familial cases and of a few recurrent variations documented a high phenotypic variability, even within a single family.Most mutations predict a truncation of the protein, but the proportion of missense variations has increased with time.

Missense variations (or small in-frame insertions/deletions) outside of the HMG domain should be considered with caution, even with good in silico pathogenicity scores. The fact that the variation is already published can be used as a supporting argument only if the strength of the published data has been verified (also a general recommendation of the American College of Medical Genetic).The most (almost fully) penetrant sign observed in patients is hearing impairment. Pigmentation defects are not always present.

Confirmed incomplete penetrance appears to be very rare, but a targeted clinical reevaluation may be necessary to assess mild signs. Searching for inner ear-specific malformations by imaging is highly informative. The absence of olfactory bulbs could be investigated at the same time by MRI.

The only strong phenotype-genotype correlation usable in phenotype prediction, thus far, is the link between NMD escape and PCW/PCWH.Ethics statementsPatient consent for publicationNot required.Ethics approvalEthics approval is not applicable. This study does not involve human participants in a research study. Only mutations found on a diagnosis basis are reviewed in a retrospective manner (list of mutations along with scarce clinical information).AcknowledgmentsWe apologise to all whose contributions were not cited due to space limitations..

IntroductionSOX10 belongs to the SOX family of transcription factors, of which the members propecia cheapest price are defined based on http://www.danielpeixe.com/mandy-talks-spanish/ the presence of a 79 amino acid DNA-binding domain with homology to the high mobility group (HMG) box of SRY (sex-determining region Y. Hence SOX, Sry bOX). These factors are involved in multiple developmental processes, such as male differentiation, skeletogenesis, neurogenesis and neural crest (NC) development, where they control stemness, cell fate and differentiation.1–4 The growing number of developmental disorders associated with mutations in SOX genes underscores their importance during development.5 The SOX10 transcription factor is a characteristic marker for migratory multipotent NC progenitors as well as for various NC derivatives.The NC is a specific population of cells in vertebrates that arise at the propecia cheapest price edge between the neural and non-neural ectoderm, delaminate from the dorsal aspect of the neural tube, and migrate through several routes to reach target tissues and give rise to neurons and glia of the peripheral nervous system (PNS), including sensory, autonomous and enteric ganglia, Schwann cells and olfactory ensheathing cells, melanocyte pigment cells, skeletal structures and mesenchyme of the head, face and neck, outflow tract of the heart, and smooth muscle cells of the great arteries.6 7Over the years, heterozygous SOX10 mutations have been associated with various phenotypes that extend beyond Waardenburg syndrome (WS.

Depigmentation features and deafness) and Hirschsprung disease (HSCR. Intestinal aganglionosis) initial diagnosis. Here, we present an up-to-date overview of these various clinical manifestations, along with our current understanding of how propecia cheapest price they are explained by SOX10 dysfunction in several NC derivatives and extra-NC tissues (inner ear and oligodendrocytes), and of the origin of phenotypic variability.SOX10.

Structure and regulation of the gene, protein domains and post-transcriptional modificationsThe human SOX10 and mouse Sox10 genes encode an open reading frame of 466 amino acids that share 92% nucleotidic and 98% amino acid sequence identities.8 The absence of a complete description of the human gene 5’ non-coding exon(s) has given rise to two coexisting exon numbering systems. Historically, exons 1 and 2 are non-coding, the initiation codon is found in exon 3, and the stop codon in exon 5.8 The second system is based on the reference transcript NM_006941, with only one non-coding exon in the 5’UTR (untranslated transcribed region) and a total of four exons. A major transcript of ~3 kb is detected in most tissues tested, consistent with the predicted SOX10 mRNA sequence.9 10The protein’s structure is schematised in figure 1 propecia cheapest price.

As for all other members of the SOX family, the previously mentioned HMG domain forms an L-shaped module composed of three alpha helices that bind to DNA sequences in the minor groove (matching or resembling C[A/T]TTG[A/T][A/T]), bending the DNA molecule and interacting with other proteins to establish stable and active transcriptional complexes3 4 (the most recent model can be found in Haseeb and Lefebvre11). This domain also harbours two nuclear import (nuclear localisation signal) and one export (nuclear export signal) signals.12 1310 samples in various tissues (including the brain, gut, nerves (tibial), breast and salivary glands)/total number of A-to-I modifications reported is. AluY.

20/73. DIM, dimerisation domain. ERK, extracellular signal-regulated kinase.

HMG, high mobility group domain. NES, nuclear export signal. NLS, nuclear localisation signal.

TA/TAC, transactivation domain in C-terminal. TAM, transactivation domain in the middle of the protein." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-2069966281" data-figure-caption="Schematic of the SOX10 protein and post-translational modifications. Domains of human SOX10.

The numbers refer to amino acid residues. The pink lines above the HMG domain represent the NLS sequences, one at each end of the HMG domain, and the light pink line the NES sequence. Note that although nucleocytoplasmic shuttling of the protein has been well documented for several SOX factors,12 13 in vivo regulation of SOX10 through nuclear translocation is yet to be clarified.

Black arrowheads represent the localisation of junctions between exons. Post-transcriptional modifications, including acetylation (Ac), phosphorylation (P) and sumoylation (Su), are indicated, along with the position of modified amino acids. Note that a putative acetylation site was identified in SOX2 and is conserved in SOX10.17 Sumoylation by Ubc9 occurs at lysines K55, K246 and K357 with consequences on cell fate decision.19 20 Mechanistically, sumoylated SOXE proteins fail to interact with the coactivator CBP (CREB-binding protein)/p300 and instead recruit the GRG4 corepressor (Groucho-related protein 4/TLE4, transducing-like enhancer of split 4), leading to strong inhibition of SOXE target genes.106 Among the identified phosphorylation sites, note that ERK phosphorylates T240 and T244, inhibiting the sumoylation of SOX10 at K55 and transcriptional activity.107 Additional phosphorylation sites have been described from large-scale proteomic screens in melanoma, breast tumours and mouse neuroblastoma (serine S8, S13, S17, S24, S27, S30, S40, S45, S221, S224 and S23216).

The relevance of most has not been functionally assessed. SOX10 phosphorylation sites are localised in two distinct clusters, one at the amino terminus, 5’ of the dimerisation domain, and the other at the centre of the protein. FBXW7-mediated ubiquitination of SOX10 has also been shown to control protein stability.

The region involves aa 235–244 of the human protein. A search of the public REDIportal (http://srv00.recas.ba.infn.it/atlas/) revealed various A-to-I editing sites located in AluY, AluSx or AluSq sequences embedded in the last SOX10 intron. In each Alu sequence schematised from left to right, the number of A-to-I sites identified in >10 samples in various tissues (including the brain, gut, nerves (tibial), breast and salivary glands)/total number of A-to-I modifications reported is.

ERK, extracellular signal-regulated kinase. HMG, high mobility group domain. NES, nuclear export signal.

NLS, nuclear localisation signal. TA/TAC, transactivation domain in C-terminal. TAM, transactivation domain in the middle of the protein." data-icon-position data-hide-link-title="0">Figure 1 Schematic of the SOX10 protein and post-translational modifications.

Domains of human SOX10. The numbers refer to amino acid residues. The pink lines above the HMG domain represent the NLS sequences, one at each end of the HMG domain, and the light pink line the NES sequence.

Note that although nucleocytoplasmic shuttling of the protein has been well documented for several SOX factors,12 13 in vivo regulation of SOX10 through nuclear translocation is yet to be clarified. Black arrowheads represent the localisation of junctions between exons. Post-transcriptional modifications, including acetylation (Ac), phosphorylation (P) and sumoylation (Su), are indicated, along with the position of modified amino acids.

Note that a putative acetylation site was identified in SOX2 and is conserved in SOX10.17 Sumoylation by Ubc9 occurs at lysines K55, K246 and K357 with consequences on cell fate decision.19 20 Mechanistically, sumoylated SOXE proteins fail to interact with the coactivator CBP (CREB-binding protein)/p300 and instead recruit the GRG4 corepressor (Groucho-related protein 4/TLE4, transducing-like enhancer of split 4), leading to strong inhibition of SOXE target genes.106 Among the identified phosphorylation sites, note that ERK phosphorylates T240 and T244, inhibiting the sumoylation of SOX10 at K55 and transcriptional activity.107 Additional phosphorylation sites have been described from large-scale proteomic screens in melanoma, breast tumours and mouse neuroblastoma (serine S8, S13, S17, S24, S27, S30, S40, S45, S221, S224 and S23216). The relevance of most has not been functionally assessed. SOX10 phosphorylation sites are localised in two distinct clusters, one at the amino terminus, 5’ of the dimerisation domain, and the other at the centre of the protein.

FBXW7-mediated ubiquitination of SOX10 has also been shown to control protein stability. The region involves aa 235–244 of the human protein. A search of the public REDIportal (http://srv00.recas.ba.infn.it/atlas/) revealed various A-to-I editing sites located in AluY, AluSx or AluSq sequences embedded in the last SOX10 intron.

In each Alu sequence schematised from left to right, the number of A-to-I sites identified in >10 samples in various tissues (including the brain, gut, nerves (tibial), breast and salivary glands)/total number of A-to-I modifications reported is. AluY. 67/224.

DIM, dimerisation domain. ERK, extracellular signal-regulated kinase. HMG, high mobility group domain.

NES, nuclear export signal. NLS, nuclear localisation signal. TA/TAC, transactivation domain in C-terminal.

TAM, transactivation domain in the middle of the protein.SOX10 shares additional domains with SOX8 and SOX9, all three forming the SOX_E group (SOX factors have been subdivided in several groups based on the amino acid identity within their HMG domain) (figure 1). Among them, the dimeric domain (DIM) confers preferential binding of SOX_E members to target sites containing two inverted SOX motifs separated by three to four nucleotides and promotes homodimerisation or heterodimerisation through DIM:HMG interactions.14Within its C-terminus, SOX10 contains a potent transactivation domain called the TA or TAC (transactivation domain in C-terminal).4 Another weaker and context-dependent transactivation domain has been identified in the middle of SOX10, the so-called K2 domain or TAM (transactivation domain in the middle of the protein), and was recently shown to synergise with TA/TAC in all SOX_E members.11 15Various post-transcriptional and post-translational modifications modulate the activity, stability and intracellular localisation of SOX1016 (figure 1). Several of these modifications are inferred from those occurring in other SOX factors, as for the lysine K136 acetylation site.16–18 Others, including phosphorylation sites, were mainly found from large-scale proteomic screens performed in cancer cells.

SOX10 sumoylation by UBC9 (sumo-conjugating enzyme UBC9) is the best described one. Occurring at lysines K55, K246 and K357,19 it inhibits NC development and promotes development of non-sensory cranial placodes in vivo.20 Absence of A-to-I RNA modification mediated by the ADAR (adenosine deaminase RNA-specific) enzyme family was recently reported to alter melanocyte and Schwann cell development.21 Examination of the public REDIportal shows that SOX10 is under such regulation in humans (but not mice).Finally, several regulatory regions likely involved in driving SOX10/Sox10 expression have been identified using various cell lines and zebrafish or mice models (ref 22 and references therein). Methylation of the Sox10 promoter by DNA methyansferase 3 has also been shown to arrest NC generation in chicks.23Involvement of SOX10 in WS.

Role in melanocytes and enteric nervous systemThe identification of Sox10 as the gene mutated in the spontaneous Dom mutant mouse (Dominant megacolon. Intestinal aganglionosis, white belly spot and white paws) first shed light on the essential function of this transcription factor in NC development. In this strain, a Sox10 frameshift mutation results in alteration of binding to some DNA target sequences in vitro, of transactivation capacity and synergistic action with several cofactors.9 24–27 This observation immediately led to test SOX10 involvement in Waardenburg-Hirschsprung disease.8 Also known as WS type 4 (WS4) or Waardenburg-Shah syndrome, Waardenburg-Hirschsprung encompasses symptoms of WS and HSCR (Mendelian inheritance in man, MIM) #613266).28–30HSCR is the most common enteric neuropathy, occurring in 1 of 5000 neonates, and is characterised by the absence of enteric ganglia from a varying length of the distal gut, leading to intestinal obstruction in neonates or severe constipation in adults (MIM #142623).29 30WS is a genetic disorder characterised by sensorineural hearing loss (SNHL) and pigmentation anomalies, including depigmented patches of skin and hair and vivid blue eyes or iris heterochromia (MIM #193500).

Four types of WS are clinically defined, based on additional features due to defects in structures mostly arising from NC derivatives. WS1 is further characterised by dystopia canthorum, WS3 by musculoskeletal abnormalities of the limbs, WS4 by HSCR, whereas WS2 has no further significant features. In addition to SOX10, four main genes are involved in WS thus far.

MITF (melanocyte inducing transcription factor) in WS2, PAX3 (transcription factor paired Box 3) in WS1 and WS3, EDN3 (endothelin 3) in WS4, and EDNRB (endothelin receptor type B) in WS4 and WS2.28 31 32 SOX10 has been shown to regulate and interact with several of these genes.28 33SOX10 screening in WS4 cases led to the identification of the first heterozygous mutations in 1998.8 In 2007, SOX10 mutations were shown to be also responsible for approximately 15% of WS2 cases.34 By contrast, SOX10 involvement in isolated HSCR is very limited. For example, screening of 229 isolated HSCR cases led to the identification of only one frameshift mutation inherited from an asymptomatic mother (germline mosaicism has been proposed).35Certain patients with WS4 or PCWH (see later) present with hypoganglionosis or chronic intestinal pseudo-obstruction (CIPO) instead of HSCR.28 36–39 Given the role of SOX10 in enteric nervous system (ENS) development, CIPO is probably neurogenic. Aganglionosis is therefore not the only mechanism underlying the intestinal dysfunction in patients with SOX10 mutations.Each of the clinical manifestations described above can be explained by dysregulation of SOX10 during melanocyte and ENS development.

WS accounts for a developmental defect in both skin melanocytes and a melanocyte-derived cell lineage of the inner ear, called intermediate cells of the stria vascularis, necessary to the inner ear homeostasis.40 In melanocytes, SOX10 controls proliferation, survival and differentiation by directly and sequentially activating a number of downstream target genes.4 41–43 From the NC, a SOX10–PAX3 pair activates the expression of Mitf/MITF, which then acts as a SOX10 partner to activate the expression of Dct (dopachrome tautomerase) and Tyr (tyrosinase), both involved in melanocyte differentiation and melanin synthesis.27 32 42 44 45 In 2015, an extensive genome-wide catalogue of SOX10 targets was obtained.46 For the first time, integrated chromatin occupancy and transcriptome analysis suggested a role of SOX10 in both transcriptional activation and repression. SOX10 was also shown to cooperate with MITF to facilitate BRG1 (Brahma-related gene 1/SMARCA4, SWI/SNF related, matrix associated, actin-dependent regulator of chromatin) binding to distal enhancers of melanocyte-specific genes, promoting differentiation.47In the developing gut, SOX10 is expressed in all NC-derived ENS progenitors.22 24 48–50 Later, SOX10 is maintained in enteric glia but downregulated in cells that are committed to neurons (see refs 25 50 for examples). Most publications suggest a role of SOX10 in the maintenance of enteric progenitors,22 49 and overexpression of SOX10 inhibits enteric neuron differentiation, without altering commitment to the neurogenic lineage.25 51 These cellular functions rely on the capacity of SOX10 to regulate (along with several cofactors) various target genes, including Ret (RET proto-oncogene.

A receptor tyrosine kinase involved in ENS development and the main HSCR-related gene), Ednrb and Sox10 itself.22 33 52 53 As an example SOX10 and ZEB2 (zinc-finger E-box binding homeobox 2. A negative regulator of NC differentiation) both bind to Ednrb promoter-specific regions, highlighting the role of this ‘triade’ in controlling the maintenance of multi-potential enteric progenitors and their differentiation process.33Hearing loss associated with SOX10 mutations. Beyond melanocytes, SOX10 expression in inner ear and related deficitsSNHL due to SOX10 mutations, as for the other WS genes, is typically prelingual, non-evolutive, profound and bilateral.

However, it can also be moderate and asymmetric or unilateral.Aside from the intermediate-cell alterations mentioned above, inner ear malformations have been noted in some patients with WS long ago.54 It now appears that only patients with a SOX10 mutation present with these abnormalities. Hypoplasia/dysplasia or agenesis of the semicircular canals and enlarged vestibules are very frequent, while agenesis of the vestibulo-cochlear nerve and cochlear deformities have also been reported.55–57 Consequently, temporal CT scan or MRI is of particular interest in diagnosis. In our experience, this feature is highly penetrant when interpreted by a specialised radiologist.

However, recent papers reported the absence of imaging abnormalities in the inner ear of a few patients with SOX10 mutations. A complete exploration of the vestibular function has yet to be performed.These observations are consistent with an expression profile of Sox10 in the ear. Sox10 is expressed in the placode-derived otic vesicle from E9.5 onward and then in the developing epithelium of the cochlea and vestibule, before being restricted to supporting cells of the neurosensory epithelium.

Sox10/SOX10 promotes the survival of cochlear progenitors during formation of the otocyst and the organ of Corti, plays a role in glial development of the cochleovestibular ganglia, and its NC-targeted deletion leads to improper neuronal migration and projection.58–60 The resulting inner ear malformations differ depending on the animal model.58 61 62 RNA-seq studies of inner ear development in a pig model showed dysregulation of WNT1 (Wnt family member 1. A regulator of cell fate and patterning), KCNQ4 (potassium voltage-gated channel subfamily Q), STRC (stereocilin. A protein associated with the hair bundle of the ear sensory cells) and PAX6 (transcription factor Paired Box 6) networks.62In agreement with this broad function, SNHL appears to be the most penetrant sign in cases of SOX10 mutation, leading to the observation that certain patients can present with isolated SNHL until minor signs are revealed on medical reinterview.63PCWH and PCW phenotypes.

Important function of SOX10 in Schwann cells and oligodendrocytesBeyond WS2 or WS4, neurological alterations have been identified in the so-called PCWH syndrome (peripheral demyelinating neuropathy, central dysmyelinating leukodystrophy, Waardenburg syndrome, Hirschsprung disease. MIM #609136).28 36 64 Depending on the severity of myelin defects in the PNS and central nervous system (CNS), patients with PCWH exhibit variable symptoms that often include delayed motor and cognitive development, cerebral palsy, ataxia, spasticity, congenital nystagmus, hyporeflexia, distal sensory impairments and distal muscle wasting. This phenotype is recapitulated in a transgenic mouse model with several copies of SOX10 carrying the first PCWH mutation described65 66 and is mostly explained by the role of SOX10 during differentiation of myelinating Schwann cells and oligodendrocytes, both ensuring rapid salutatory conduction along axons.67 68In the PNS, SOX10 controls each differentiation step by inducing stage-restricted transcriptional regulators, which are then recruited as partners to activate specific sets of target genes, allowing progression to the next stage.67–72 For example, in immature Schwann cells, SOX10 induces the expression of OCT6 (POU3F1, POU class 3 homeobox 1).

Both factors then cooperatively activate the programme required for progression into the promyelinating stage. Their target EGR2 (early growth response 2) then associates with SOX10 to activate the myelination programme.In the CNS, analyses of various animal models revealed an essential role of SOX10 in the terminal differentiation of oligodendrocytes in coordination with OLIG1 (OLIGodendrocyte transcription factor 1), MYRF (myelin regulatory factor), TCF4 (transcription factor 4, which has an important role in CNS development) and CHD7 (chromodomain helicase DNA-binding protein 7. The gene involved in CHARGE syndrome (Coloboma, Heart anomaly, choanal Atresia, Retardation, Genital and Ear anomalies)).68 Many genes that are activated during terminal differentiation of oligodendrocytes are direct targets of SOX10, but there are only few known SOX10 targets in oligodendrocyte precursors.68 73 74 Recently, MYRF was identified as a decisive factor that helps SOX10 to switch between its target genes along oligodendrocyte differentiation process.75Of interest, some of the genes directly regulated by SOX10 in PNS and CNS are known to be responsible for hypomyelinating/demyelinating diseases, with some described mutations in these genes that directly result from a loss of regulation by SOX10.76–78Involvement of SOX10 in Kallmann syndrome and its role in olfactory ensheathing cellsSOX10 was considered to be a candidate gene for Kallmann syndrome (KS, hypogonadotropic hypogonadism and anosmia.

MIM #308700) based on the unexpected high frequency of olfactory bulb agenesis55 associated with rare clinical reports of hypogonadism or anosmia in patients with WS/PCWH with a SOX10 mutation. The screening of cohorts indeed revealed SOX10 mutations in patients with KS, most of whom also have hearing impairment.79 Since then, many other SOX10 mutations have been characterised in KS or normosmic idiopathic hypogonadotropic hypogonadism (nIHH), although they were usually not functionally characterised and a subset of them appeared unlikely to be pathogenic (see Review of SOX10 variations). Interestingly, KS and WS are not mutually exclusive, and some patients with an initial diagnosis of WS have been further diagnosed with hypogonadism at puberty.80 We believe that anosmia and hypogonadism are still underestimated in patients with WS with a SOX10 mutation, as signs of KS are difficult to diagnose before puberty.

Of note, in the absence of pigmentary disturbances, the association of KS+hearing impairment+abnormalities of the semicircular canals can lead to a differential diagnosis with mild forms of CHARGE syndrome (MIM #214800) (examples in online supplemental table 1).Supplemental materialThe common cause of anosmia and hypogonadism is a defect in a developmental sequence of GnRH (gonadotropin-releasing hormone) neurons migrating along the peripheral olfactory nerve up to and through the olfactory bulb. In the Sox10 knockout mouse, a primary defect of the olfactory ensheathing cells leads to a secondary defect of the olfactory nerve pathway, defasciculation and misrouting of the nerve fibres, impaired migration of GnRH cells along this route, and disorganisation of the olfactory nerve layer of the olfactory bulbs.79 Dysregulation of the frizzled related protein FRZB may contribute to explain the defect in olfactory axon targeting but not GnRH neuron migration.81A summary of the recurrent clinical manifestations due to constitutive SOX10 mutations along with affected cell types is presented in figure 2.Summary of the clinical spectrum due to SOX10 mutations and the corresponding SOX10 function(s). The picture is organised around three clinical poles that correspond to different diagnosis entries.

The WS pole is indicated in red, the myelin pole in blue and the KS pole in green. The plain line corresponds to the definition of the disease, while the dotted lines indicate the main clinical extension of these syndromes in case of SOX10 mutation. Note that the area of the circles is not proportionate to the relative frequency of each syndrome (for an idea about the number of patients, see figure 3B).

CIPO, chronic intestinal pseudo-obstruction. CNS, central nervous system. ENS, enteric nervous system.

GnRH, gonadotropin-releasing hormone. HSCR, Hirschsprung disease. KS, Kallmann syndrome.

NIHH, normosmic idiopathic hypogonadotropic hypogonadism. PCWH, peripheral demyelinating neuropathy, central dysmyelination, Waardenburg syndrome, with Hirschsprung disease. PNS, peripheral nervous system.

SNHL, sensorineural hearing loss. WS, Waardenburg syndrome. WS2, Waardenburg syndrome type 2.

WS4, Waardenburg syndrome type 4." data-icon-position data-hide-link-title="0">Figure 2 Summary of the clinical spectrum due to SOX10 mutations and the corresponding SOX10 function(s). The picture is organised around three clinical poles that correspond to different diagnosis entries. The WS pole is indicated in red, the myelin pole in blue and the KS pole in green.

The plain line corresponds to the definition of the disease, while the dotted lines indicate the main clinical extension of these syndromes in case of SOX10 mutation. Note that the area of the circles is not proportionate to the relative frequency of each syndrome (for an idea about the number of patients, see figure 3B). CIPO, chronic intestinal pseudo-obstruction.

CNS, central nervous system. ENS, enteric nervous system. GnRH, gonadotropin-releasing hormone.

HSCR, Hirschsprung disease. KS, Kallmann syndrome. NIHH, normosmic idiopathic hypogonadotropic hypogonadism.

PCWH, peripheral demyelinating neuropathy, central dysmyelination, Waardenburg syndrome, with Hirschsprung disease. PNS, peripheral nervous system. SNHL, sensorineural hearing loss.

WS, Waardenburg syndrome. WS2, Waardenburg syndrome type 2. WS4, Waardenburg syndrome type 4.Involvement in cancer, sex reversal, associations and reports of the first biallelic mutationsBeyond congenital disorders, a role of SOX10 in cancer progression has been reported.

SOX10 protein is highly expressed in breast, glioma, glioblastoma, salivary adenoid cystic tumours and hepatocellular carcinoma (see The Cancer Genome Atlas). The association of SOX10 with melanoma is the best described, but only a limited number of variants have been reported so far.82–84Several reports of duplications in the 22q13.1 region have been published that may include one or several signs of WS/PCWH and sex reversal in a number of cases.85 Sex reversal has been suggested to be due to the overexpression of SOX10, consistent with observations in a Sox10 transgenic mouse model.86 However, we found a SOX10 triplication (four doses of SOX10 instead of two) in a 47,XX baby girl without sex reversal (online supplemental table 1), indicating that overexpression of SOX10 alone may not be sufficient, the sign is not fully penetrant or the overexpression of other genes has the opposite effect, depending on the size of the rearrangement.More complex and questionable associations have also been described. For example, increased DNA methylation of SOX10 has been linked to oligodendrocyte dysfunction in patients with schizophrenia.87Two cases of biallelic SOX10 deletion have been characterised and, although not reported in the papers, they appear to represent the first and second pregnancy from the same couple.88 89 Both parents are heterozygous for one of the two SOX10 deletions and present with a classic form of WS.

Biallelic SOX10 loss-of-function results in a severe polymalformative fetal phenotype. Eighteen other genes were included in the maternal deletion and may participate in the phenotype.Finally, the development of large gene panels for diagnosis and whole exome/whole genome sequencing has led to SOX10 mutations being found in unexpected contexts. A number of cases have thus been listed in cohorts of neurodevelopmental defects, hearing impairment and endocrinological problems.

Due to the diverse phenotypes related to SOX10 mutations, making sense of such findings can be challenging.Review of SOX10 variationsDuring the first 15 years after their discovery, most SOX10 disease-associated point mutations were shown to result in premature termination codons, with strikingly few exceptions.28 Missense mutations started to be found simultaneously with the finding that SOX10 mutations can cause less severe syndromes than life-threatening WS4 or PCWH.90An up-to-date summary of confident mutations of SOX10 (approximately 300 independent cases, including unpublished ones in online supplemental table 1) is presented in figure 3A. Truncations (stops, frameshifts) are found in slightly more than half of all cases. Approximately one-third of all mutations are non-truncating variations, either missense or small inframe insertions/deletions, the rest being either complete or partial copy number variations of the gene (approximately 10%) and rare mutational mechanisms (splice mutations, mutation of the initiation codon or non-stop mutations (five cases to date)).

Truncating mutations can be located anywhere, except in the very extreme C-terminus. On the contrary, missense mutations are tightly clustered in the DNA-binding domain (HMG), a frequent finding for transcription factors. We have thus far found no specific link between SOX10 missense mutations and residues involved in post-translational modifications.Review of SOX10 mutations.

(A) Representation of SOX10 truncating and non-truncation mutations along the SOX10 protein. We made a list of all published SOX10 mutations, starting with the LOVD database that we curated up to 2015 (https://databases.lovd.nl/shared/genes/SOX10), updated with the literature and finally completed using the HGMD (Human Gene Mutation Database) professional database (https://digitalinsights.qiagen.com/products-overview/clinical-insights-portfolio/human-gene-mutation-database) for a few mutations that were reported in cohorts of unspecific diagnosis and would have been missed by common keywords. We prioritised the strength of the data to create this figure, as our goal was not to include all cases but to provide a reliable picture of the SOX10 mutational spectrum.

We retained papers for which the data allowed curation and removed neutral variants and variants of unknown significance, duplicated patients or publications, and publications with inconsistent findings. Finally, we added our unpublished cases (listed in online supplemental table 1). €˜M1?.

€™ indicates a mutation of the initiation codon (p.Met1?. ). (B) Proportion (in percentage) of the different types of mutations for each syndrome.

€˜n’ indicates the number of independent cases included in each group. (C) Localisation of the truncating (stop and frameshift) mutations along the SOX10 protein associated with each phenotype. Note that (1) the phenotypic description was sometimes too incomplete for inclusion in B and C.

(2) among the familial cases showing intrafamilial differences in phenotype, we considered the phenotype of the index case. (3) KS/nIHH is given regardless of the presence of WS signs or not, and anosmia without hypogonadism was not considered. And (4) because presence or absence of a demyelination is frequently unreported or not evaluated, we conserved all the patients with neurological features in the PCW/PCWH group when the data seemed consistent.

DIM, dimeric domain. HMG, high mobility group. KS, Kallmann syndrome.

LOVD, Leiden OPen Variation Database. NIHH, normosmic idiopathic hypogonadotropic hypogonadism. PCW/PCWH, peripheral demyelinating neuropathy, central demyelination, Waardenburg syndrome, with or without Hirschsprung disease.

TA, transactivation domain in C-terminal. TAM, transactivation domain in the middle of the protein. WS, Waardenburg syndrome.

WS2, Waardenburg syndrome type 2. WS4, Waardenburg syndrome type 4." data-icon-position data-hide-link-title="0">Figure 3 Review of SOX10 mutations. (A) Representation of SOX10 truncating and non-truncation mutations along the SOX10 protein.

We made a list of all published SOX10 mutations, starting with the LOVD database that we curated up to 2015 (https://databases.lovd.nl/shared/genes/SOX10), updated with the literature and finally completed using the HGMD (Human Gene Mutation Database) professional database (https://digitalinsights.qiagen.com/products-overview/clinical-insights-portfolio/human-gene-mutation-database) for a few mutations that were reported in cohorts of unspecific diagnosis and would have been missed by common keywords. We prioritised the strength of the data to create this figure, as our goal was not to include all cases but to provide a reliable picture of the SOX10 mutational spectrum. We retained papers for which the data allowed curation and removed neutral variants and variants of unknown significance, duplicated patients or publications, and publications with inconsistent findings.

Finally, we added our unpublished cases (listed in online supplemental table 1). €˜M1?. €™ indicates a mutation of the initiation codon (p.Met1?.

). (B) Proportion (in percentage) of the different types of mutations for each syndrome. €˜n’ indicates the number of independent cases included in each group.

(C) Localisation of the truncating (stop and frameshift) mutations along the SOX10 protein associated with each phenotype. Note that (1) the phenotypic description was sometimes too incomplete for inclusion in B and C. (2) among the familial cases showing intrafamilial differences in phenotype, we considered the phenotype of the index case.

(3) KS/nIHH is given regardless of the presence of WS signs or not, and anosmia without hypogonadism was not considered. And (4) because presence or absence of a demyelination is frequently unreported or not evaluated, we conserved all the patients with neurological features in the PCW/PCWH group when the data seemed consistent. DIM, dimeric domain.

HMG, high mobility group. KS, Kallmann syndrome. LOVD, Leiden OPen Variation Database.

NIHH, normosmic idiopathic hypogonadotropic hypogonadism. PCW/PCWH, peripheral demyelinating neuropathy, central demyelination, Waardenburg syndrome, with or without Hirschsprung disease. TA, transactivation domain in C-terminal.

TAM, transactivation domain in the middle of the protein. WS, Waardenburg syndrome. WS2, Waardenburg syndrome type 2.

WS4, Waardenburg syndrome type 4.Of course, rarity in control populations is not sufficient to confer pathogenicity and the prediction of pathogenicity by dedicated tools is of indicative value only. Among the published SOX10 missense variations that are located outside of the HMG domain, most should be considered variants of unknown significance. From our experience and bibliography review, it appears that extremely rare or new missense variations have a high probability of being truly pathogenic if located in the HMG domain, whereas missense mutations located outside of this domain, even if rare and ‘predicted pathogenic’ by in silico tools, are less likely to be pathogenic and should be considered cautiously.

We have worked on SOX10 since its characterisation, both in the research and clinical context, and have only once found an exception to each of these rules. With the increasing number of mutations described, it appears that there may be a second, rare spot of mutations in the dimerisation domain (three variations reported in four independent cases, creating or removing valines at residues 76, 79 and 80), although functional tests are required to reach a definitive conclusion91 92 (online supplemental table 1).Due to the well-documented incomplete penetrance and digenism in KS and nIHH, there is a tendency in the literature to overevaluate the pathogenic probability of rare variants. Certain SOX10 variations have been considered to be pathogenic or likely pathogenic without many arguments (low pathogenicity scores, no functional tests, proven not pathogenic in another paper, inherited from healthy parents or without segregation study, and/or associated with an obvious causative mutation in another KS/nIHH gene).

On careful review, we consider several of these rare missense variants to more likely be neutral (although some still may be hypomorphic variants exerting their effect on a multigenic background, but this has thus far not been proven) and did not include them in figure 3.In early studies, most SOX10 variants were found to be de novo, which was thought to be due to the severity of HSCR in WS4. Given the cumulative number of WS2 cases now described, the life-threatening hypothesis cannot completely explain the proportion of de novo mutations. The possibility of hypogonadism in patients probably also contributes to this observation.

However, the proportion of familial cases has tended to increase over the years and now represents approximately 20% of cases. These cases revealed an important intrafamilial phenotypic variability. Several mutations have now been found in independent cases and also show interfamilial phenotypic variability.

Parental mosaicism is found in approximately 3%–4% of cases, but a recent study reported a higher proportion in a small series using more sensitive methods.93The proportion of mutations relating to phenotype is summarised in figure 3B. There is a large proportion of truncating mutations in WS4 and PCWH. The proportion of missense increases in WS2 and even more strongly in KS.

Thus, not all missense mutations may be null mutations.The location of truncating mutations along the gene (figure 3C) confirms the correlation between PCWH and the escape from non-sense-mediated RNA decay (NMD) (mutations located in the last coding exon and last 45 nt of the penultimate exon).64 Of note, some of the cases that appear not to respect the NMD rule may be misclassified (whether demyelination is proven or not is not always reported). The severity of PCWH was shown to be linked to the location of the mutation within the last exon. The earlier the truncation, the more severe the phenotype.64 This tendency is visible in the graphs (compare the truncating mutations of WS vs PCWH in the last exon).

A few cases escape the rule, with no clear explanation so far.Finally, heterozygous deletions/duplications can be intragenic or lead to complete gene loss and be as large as several Mb, encompassing other genes and leading to more complex phenotypes.Functional consequences of SOX10 mutations and the origin of phenotypic variabilityMost in vitro functional tests found in the literature rely on the ability of SOX10 to activate its target genes, alone or in combination with its cofactors. The construct most frequently used is a luciferase reporter under the control of the MITF-M (melanocyte-specific isoform) promoter. Additional targets, immunohistochemistry and assessment of the contribution of the DNA-binding capabilities have sometimes enriched such studies.Functional analysis of the first SOX10 missense mutation suggested that differential tissue-specific gene regulation could account for the phenotype observed in patients.94–96 Since, many SOX10 missense mutations associated with a variety of phenotypes, ranging from WS2 to WS4 and PCWH, have been tested, but no clear correlation between in vitro results and the phenotypes could be established.79 90 97The development of in vivo tests is therefore required to facilitate the establishment of genotype–phenotype correlations.

The only model currently published is in ovo chick electroporation in the developing neural tube.26 However, the effect of most of the mutations on early NC development precludes the analysis of their role in later developmental processes. Use of an inducible model would be of interest. Alternatively, zebrafish or the use of induced pluripotent stem cells differentiated towards NC derivatives of interest could be future models of choice.As mentioned earlier, the presence or absence of a neurological phenotype that characterises PCWH or PCW was proposed to be related to NMD.64 The proposed mechanism is that mutant proteins that have escaped degradation via the NMD pathway result in dominant-negative activity that impairs the function of the wildtype SOX10 allele and lead to PCWH, while those located in the first coding exons activate the NMD RNA surveillance pathway, leading to degradation, haploinsufficiency and a classic WS phenotype.However, several non-stop mutations have also been described to be associated with a PCW/PCWH phenotype.

This is thought to be due to the generation of a specific inframe new C-terminus generated by the loss of normal termination. Functional studies of an equivalent mouse mutant allele showed that the additional 82 amino acids contain a deleterious (tryptophan-arginine (WR) domain, supporting a toxic gain-of-function.98 This is consistent with the recent report of a frameshift mutation that also elongates the protein, but in a different reading frame does not lead to PCWH (p.Tyr460Leufs*42).99 The observation of another, transgenic mouse model carrying different copy number variations of the first described SOX10 non-stop mutation suggested PCWH is due to a dominant-additive, rather than dominant-negative, effect.66 Finally, duplication of the 22q13.1 region, including SOX10, can also induce PCWH,85 supporting the hypothesis that it is promoted by a gain-of-function rather than a dominant-negative effect. Regardless of the mechanism, these observations all indicate that NC derivatives are highly sensitive to the dose of SOX10 and its function.SOX10 expression is regulated by numerous enhancers.

It is thus possible that certain cases with minor expression could also be due to specific dysregulation of one or a subset of such enhancers. This paradigm is supported by disruption of tissue-specific, long-distance regulatory regions of SOX9 causing endophenotypes.100 101 A large de novo deletion encompassing three SOX10 regulatory elements has been characterised in a patient with typical WS4,102 leading to the hypothesis that variations affecting certain identified regulatory sequences could be the cause of unexplained WS2 or isolated HSCR. Screening for mutations in SOX10 regulatory regions in WS2 turned out to be unfruitful.103 On the contrary, one deletion and two point variations affecting binding sites for known NC transcription factors were identified in 3 of 144 cases of isolated HSCR, both variations being in association with a HSCR-predisposition polymorphism at the RET locus.104 With the implementation of population databases, it now appears that one of these two variants is less rare than expected (22-38016774 G-C.

About 1/1000 according to the gnomAD database. Https://gnomad.broadinstitute.org/), which questions its involvement. These results are yet to be replicated for a pertinent interpretation.In any case, in vitro/in vivo tests will not be able to explain all phenotypes, as phenotypic variability is commonly recognised in patients with SOX10 mutations, even those with the same mutation and even within the same family.

This suggests that the genetic background is influential, as has often been suggested for HSCR.53 105 Because the identification of modifier genes has been hampered by the small number of available patients, most modifier gene studies have relied on Sox10 mouse models.22Despite such variability, certain specificities have been reported for a few peculiar missense mutations. Here, we want to discuss the case of the Gln174/Pro175 missense mutations. The observation that certain SOX10 missense mutants accumulate in nuclear foci in transfected cells, where they colocalise with p54NRB (nucleo ribo binding protein, 54 kDa/NONO, non-Pou domain containing octamer binding.

A multifunctional protein known to be a marker of ‘paraspeckles’), leads to characterise missense mutations of amino acids 174 and 175 as associated with a peculiar phenotype (refs 79 97 and unpublished data (S. Marlin, N. Bondurand and V.

Pingault, 2016)). Remarkably, the cotransfection of foci-forming mutant with wildtype constructs led to the sequestration of wildtype SOX10 in these ‘foci’ and altered the synergistic activity of SOX10 and p54NRB. A dominant-negative effect was therefore proposed to contribute to or be at the origin of the progressive central and peripheral neurological phenotypes observed in patients carrying these specific missense mutations and may thus be the basis of a hitherto unexplored molecular mechanism for genotype–phenotype correlations.

These data need to be confirmed in more physiological models.The phenotype variability finally leads to question the risk of a more severe phenotype in cases of recurrence in a family. The risk of the PCWH phenotype after a first non-PCWH case is considered to be low. On the contrary, there is a risk of WS4 after a first, milder case of WS2.

This situation has been reported several times. However, a bias in the representation of these cases in the literature can be expected, as a second mildly affected member is less likely to result in a visit of the family to the geneticist’s office, molecular analysis and ultimately publication. As a result, the true risk is difficult to quantify.Conclusion, with a few tips to help in variant classificationDuring twenty years of cases and cohorts reporting, SOX10 variants have been involved in WS2/WS4/PCWH/Kallmann syndrome/pseudo-isolated hearing loss/HSCR or CIPO and any combination.

This is correlated with the known developmental functions of SOX10. All these phenotypes should be considered as a clinical continuum with variable expression, rather than as independent diseases, conferring a mild to life-threatening syndrome. Observation of the familial cases and of a few recurrent variations documented a high phenotypic variability, even within a single family.Most mutations predict a truncation of the protein, but the proportion of missense variations has increased with time.

Missense variations (or small in-frame insertions/deletions) outside of the HMG domain should be considered with caution, even with good in silico pathogenicity scores. The fact that the variation is already published can be used as a supporting argument only if the strength of the published data has been verified (also a general recommendation of the American College of Medical Genetic).The most (almost fully) penetrant sign observed in patients is hearing impairment. Pigmentation defects are not always present.

Confirmed incomplete penetrance appears to be very rare, but a targeted clinical reevaluation may be necessary to assess mild signs. Searching for inner ear-specific malformations by imaging is highly informative. The absence of olfactory bulbs could be investigated at the same time by MRI.

The only strong phenotype-genotype correlation usable in phenotype prediction, thus far, is the link between NMD escape and PCW/PCWH.Ethics statementsPatient consent for publicationNot required.Ethics approvalEthics approval is not applicable. This study does not involve human participants in a research study. Only mutations found on a diagnosis basis are reviewed in a retrospective manner (list of mutations along with scarce clinical information).AcknowledgmentsWe apologise to all whose contributions were not cited due to space limitations..

Trt propecia

Families and friends who have lost a loved one to suicide will now have access to a range of useful supports thanks to the NSW Government's $4.5 million boost to post-suicide services across the State.Minister trt propecia for Mental Health Bronnie Taylor said that post-suicide support was critical to support buy real propecia online loved ones as well as the wider community. "We know that around 135 people can be impacted by a single suicide," Mrs Taylor said."For friends and family, the death of a loved one by suicide is not only heartbreaking and shocking, it can also create new challenges as well as making day-to-day tasks incredibly difficult."We want to be there for people in these painful weeks and months in ways that can really help, from providing counselling to helping them access financial assistance and guiding them through the coronial process."StandBy Support After Suicide will provide the service in trt propecia partnership with Jesuit Social Services, Roses in the Ocean and University of New England. StandBy will focus on reaching bereaved families and friends, as well as first responders and witnesses to suicide.StandBy Regional Coordinator Tania Tuckerman said she draws on her own lived experience to help those affected feel safe and understood."My hope is that all people impacted by suicide will have the trt propecia support I never had," Ms Tuckerman said. "It didn't hit me trt propecia until decades later the http://www.em-leonard-vinci-strasbourg.ac-strasbourg.fr/periscolaire/infos/ full devastation it had on my life.

Including my relationships and how I interacted with the world around me."I am hopeful about the difference our support will bring to the lives of trt propecia people impacted by suicide and their future generations."The state-wide rollout of post-suicide support services is thanks to a joint investment by the NSW and Commonwealth Governments. To find out more or to access these services, please call 1300 727 247 at any time or visit StandBy – Support After Suicide.If you, or someone you know, is thinking about suicide or experiencing a personal crisis or distress, please seek help immediately by calling 000 (Triple Zero).For anyone who is struggling, you can call the below helplines for support and advice:Lifeline 13 11 14 | Kids Helpline 1800 55 1800 | NSW Mental Health Line 1800 011 511.

Families and friends who have lost a loved one to suicide will now have access to a range of useful supports thanks to the NSW Government's $4.5 million propecia cheapest price boost to post-suicide services across the State.Minister for Mental Health Bronnie Taylor said that post-suicide support was critical to support loved ones as well as the wider community. "We know that around 135 people can be impacted by a single suicide," Mrs Taylor said."For friends and family, the death of a loved one by suicide is not propecia cheapest price only heartbreaking and shocking, it can also create new challenges as well as making day-to-day tasks incredibly difficult."We want to be there for people in these painful weeks and months in ways that can really help, from providing counselling to helping them access financial assistance and guiding them through the coronial process."StandBy Support After Suicide will provide the service in partnership with Jesuit Social Services, Roses in the Ocean and University of New England. StandBy will focus on reaching bereaved families and friends, as well as first responders and witnesses to suicide.StandBy Regional Coordinator Tania Tuckerman said she draws on her own lived experience propecia cheapest price to help those affected feel safe and understood."My hope is that all people impacted by suicide will have the support I never had," Ms Tuckerman said. "It didn't hit me until decades later the full devastation it propecia cheapest price had on my life.

Including my relationships and how I interacted with the world around me."I am hopeful about the difference our support will bring to the lives of people impacted by suicide and their future generations."The state-wide rollout of post-suicide support services propecia cheapest price is thanks to a joint investment by the NSW and Commonwealth Governments. To find out more or to access these services, please call 1300 727 247 at any time or visit StandBy – Support After Suicide.If you, or someone you know, is thinking about suicide or experiencing a personal crisis or distress, please seek help immediately by calling 000 (Triple Zero).For anyone who is struggling, you can call the below helplines for support and advice:Lifeline 13 11 14 | Kids Helpline 1800 55 1800 | NSW Mental Health Line 1800 011 511.